

GenCore version 6.2.1  
Copyright (c) 1993 - 2007 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: August 16, 2007, 22:48:51 ; Search time 73 Seconds  
(without alignments)  
43.032 Million cell updates/sec

Title: US-10-715-895A-4

Perfect score: 105  
Sequence: 1 PVLDFRELLNELLEALKQKLK 22

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 983262 seqs, 142787483 residues

Total number of hits satisfying chosen parameters: 983262

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA: +  
1: /EMC\_Celerra\_SID2/prodata/1/iaa/5 COMB.pap.\*  
2: /EMC\_Celerra\_SID2/prodata/1/iaa/6 COMB.pap.\*  
3: /EMC\_Celerra\_SID2/prodata/1/iaa/7 COMB.pap.\*  
4: /EMC\_Celerra\_SID2/prodata/1/iaa/H COMB.pap.\*  
5: /EMC\_Celerra\_SID2/prodata/1/iaa/PCTUS COMB.pap.\*  
6: /EMC\_Celerra\_SID2/prodata/1/iaa/RE COMB.pap.\*  
7: /EMC\_Celerra\_SID2/prodata/1/iaa/backfiles1.pap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	105	100.0	22	2 US-08-940-095-4	Sequence 4, Appli
2	105	100.0	22	2 US-08-940-095-30	Sequence 30, Appl
3	105	100.0	22	2 US-08-940-095-100	Sequence 100, App
4	105	100.0	22	2 US-08-940-093-4	Sequence 4, Appli
5	105	100.0	22	2 US-08-940-093-30	Sequence 30, Appl
6	105	100.0	22	2 US-08-940-093-100	Sequence 100, App
7	105	100.0	22	2 US-08-940-096-4	Sequence 4, Appli
8	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
9	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
10	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
11	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
12	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
13	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
14	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
15	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
16	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
17	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
18	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
19	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
20	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
21	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
22	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
23	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
24	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl
25	105	100.0	22	2 US-08-940-096-100	Sequence 100, App
26	105	100.0	22	2 US-08-940-096-30	Sequence 30, Appl

27 105 100.0 22 2 US-09-453-833-30 Sequence 30, Appli  
28 105 100.0 22 2 US-09-453-833-100 Sequence 100, App  
29 105 100.0 22 2 US-09-453-826-4 Sequence 4, Appli  
30 105 100.0 22 2 US-09-453-826-30 Sequence 30, Appli  
31 105 100.0 22 2 US-09-453-826-100 Sequence 100, App  
32 105 100.0 22 2 US-09-453-840-4 Sequence 4, Appli  
33 105 100.0 22 2 US-09-453-840-30 Sequence 30, Appli  
34 105 100.0 22 2 US-09-453-840-100 Sequence 100, App  
35 105 100.0 22 2 US-09-865-989-4 Sequence 4, Appli  
36 105 100.0 22 2 US-09-865-989-30 Sequence 30, Appli  
37 105 100.0 22 2 US-09-865-989-100 Sequence 100, App  
38 105 100.0 22 2 US-09-453-834-4 Sequence 4, Appli  
39 105 100.0 22 2 US-09-453-834-30 Sequence 30, Appli  
40 105 100.0 22 2 US-09-453-834-100 Sequence 100, App  
41 105 100.0 22 2 US-10-283-599-4 Sequence 4, Appli  
42 105 100.0 22 2 US-10-283-599-30 Sequence 30, Appli  
43 105 100.0 22 2 US-10-283-599-100 Sequence 100, App  
44 105 100.0 22 2 US-09-465-718-4 Sequence 4, Appli  
45 105 100.0 22 2 US-09-465-718-30 Sequence 30, Appli

#### ALIGNMENTS

#### RESULT 1

US-08-940-095-4

; Sequence 4, Application US/08940095

; Patent No. 6004925

; GENERAL INFORMATION:

; APPLICANT: Dasseux, Jean-Louis

; APPLICANT: Sekul, Renate

; APPLICANT: Buttner, Klaus

; APPLICANT: Cornut, Isabelle

; APPLICANT: Metz, Gunther

; APPLICANT: Dufourcq, Jean

; TITLE OF INVENTION: APOLOPROTEIN A-1 AGONISTS

; NUMBER OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Pennie & Edmonds LLP

; STREET: 1155 Avenue of the Americas

; CITY: New York

; STATE: NY

; COUNTRY: USA

; ZIP: 10036-2811

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSeq Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/940,095

; FILING DATE: 29-SEP-1997

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Coruzzi, Laura A

; REGISTRATION NUMBER: 30,742

; REFERENCE/DOCKET NUMBER: 009196-0004-999

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650-493-4935

; TELEFAX: 650-493-5556

; TELEX: 66141 PENNIE

; INFORMATION FOR SEQ ID NO: 4:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 22 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: No. 6004925e

US-08-940-095-4

Query Match 100.0%; Score 105; DB 2; Length 22;  
Best Local Similarity 100.0%; Pred. No. 4.9e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22  
Db 1 PVLDFRELLNELLEALKQKLIK 22

## RESULT 2

US-08-940-095-30  
; Sequence 30, Application US/08940095  
; Patent No. 6004925  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; APPLICANT: Sekul, Renate  
; APPLICANT: Buttner, Klaus  
; APPLICANT: Cornut, Isabelle  
; APPLICANT: Metz, Gunther  
; APPLICANT: Dufourcq, Jean  
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS  
; NUMBER OF SEQUENCES: 258  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/940,095  
; FILING DATE: 29-SEP-1997  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0004-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEFAX: 650-493-5556  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 30:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 22 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: No. 6004925e  
; FEATURE:  
; NAME/KEY: Other  
; LOCATION: 1...22  
; OTHER INFORMATION: N-terminal dansylated peptide

US-08-940-095-30  
Query Match 100.0%; Score 105; DB 2; Length 22;  
Best Local Similarity 100.0%; Pred. No. 4.9e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22  
Db 1 PVLDFRELLNELLEALKQKLIK 22

## US-08-940-095-30

Query Match 100.0%; Score 105; DB 2; Length 22;  
Best Local Similarity 100.0%; Pred. No. 4.9e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22  
Db 1 PVLDFRELLNELLEALKQKLIK 22

## RESULT 3

US-08-940-095-100  
; Sequence 100, Application US/08940095  
; Patent No. 6004925  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; APPLICANT: Sekul, Renate  
; APPLICANT: Buttner, Klaus  
; APPLICANT: Cornut, Isabelle  
; APPLICANT: Metz, Gunther  
; APPLICANT: Dufourcq, Jean  
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS  
; NUMBER OF SEQUENCES: 258  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/940,095  
; FILING DATE: 29-SEP-1997  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0004-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEFAX: 650-493-5556  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 100:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 22 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: No. 6004925e  
; FEATURE:  
; NAME/KEY: Other  
; LOCATION: 1...22  
; OTHER INFORMATION: All amino acids are in the D-configuration

US-08-940-095-100  
Query Match 100.0%; Score 105; DB 2; Length 22;  
Best Local Similarity 100.0%; Pred. No. 4.9e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22  
Db 1 PVLDFRELLNELLEALKQKLIK 22

## RESULT 4

US-08-940-093-4  
; Sequence 4, Application US/08940093  
; Patent No. 6037323  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; APPLICANT: Sekul, Renate  
; APPLICANT: Buttner, Klaus  
; APPLICANT: Cornut, Isabelle  
; APPLICANT: Metz, Gunther

```
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; NUMBER OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/940,093
; FILING DATE: 29-SEP-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6037323e
; US-08-940-093-4
;
; Query Match 100.0%; Score 105; DB 2; Length 22;
; Best Local Similarity 100.0%; Pred. No. 4.9e-07;
; Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Qy 1 PVLDFRELLNELLEALKQKLLK 22
Db 1 PVLDFRELLNELLEALKQKLLK 22
;
; RESULT 5
; US-08-940-093-30
; Sequence 30, Application US/08940093
; Patent No. 6037323
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
```

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/940,093
; FILING DATE: 29-SEP-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6037323e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: N-terminal dansylated peptide
; US-08-940-093-30
;
; Query Match 100.0%; Score 105; DB 2; Length 22;
; Best Local Similarity 100.0%; Pred. No. 4.9e-07;
; Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Qy 1 PVLDFRELLNELLEALKQKLLK 22
Db 1 PVLDFRELLNELLEALKQKLLK 22
;
; RESULT 6
; US-08-940-093-100
; Sequence 100, Application US/08940093
; Patent No. 6037323
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/940,093
; FILING DATE: 29-SEP-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
```

```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6037323e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: All amino acids are in the D-configuration
;
US-08-940-093-100
Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 PVLDFRELLNELLEALKQK 22
Db 1 PVLDFRELLNELLEALKQK 22

RESULT 7
US-08-940-096-4
; Sequence 4, Application US/08940096
; Patent No. 6046166
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/940,096
; FILING DATE: 29-SEP-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6046166e

US-08-940-096-30
Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 PVLDFRELLNELLEALKQK 22
Db 1 PVLDFRELLNELLEALKQK 22

RESULT 8
US-08-940-096-30
; Sequence 30, Application US/08940096
; Patent No. 6046166
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/940,096
; FILING DATE: 29-SEP-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6046166e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: N-terminal dansylated peptide
;
US-08-940-096-30
Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 PVLDFRELLNELLEALKQK 22
Db 1 PVLDFRELLNELLEALKQK 22
```

```
RESULT 9
US-08-940-096-100
; Sequence 100, Application US/08940096
; Patent No. 6046166
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION NUMBER: US/08/940,096
; FILING DATE: 29-SEP-1997
; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6046166e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: All amino acids are in the D-configuration
US-08-940-096-100
Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22
| | | | | | | | | | | | | | | | | | | |
Db 1 PVLDFRELLNELLEALKQKLIK 22
| | | | | | | | | | | | | | | | | | | |

RESULT 10
US-09-465-719-4
; Sequence 4, Application US/09465719
; Patent No. 6265377
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION NUMBER: US/09/465,719
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/940,093
; FILING DATE: 29-SEP-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6265377e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: All amino acids are in the D-configuration
US-09-465-719-4
Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22
| | | | | | | | | | | | | | | | | | | |
Db 1 PVLDFRELLNELLEALKQKLIK 22
| | | | | | | | | | | | | | | | | | | |

RESULT 11
US-09-465-719-30
; Sequence 30, Application US/09465719
; Patent No. 6265377
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 08/940,093
; FILING DATE: 29-SEP-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6265377e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: All amino acids are in the D-configuration
US-09-465-719-4
Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22
| | | | | | | | | | | | | | | | | | | |
Db 1 PVLDFRELLNELLEALKQKLIK 22
| | | | | | | | | | | | | | | | | | | |
```

```
; APPLICATION NUMBER: US/09/465,719
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION NUMBER: 08/940,093
; FILING DATE: 29-SEP-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. 6265377e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: N-terminal dansylated peptide
; US-09-465-719-30

Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQK 22
Db 1 PVLDFRELLNELLEALKQK 22

RESULT 12
US-09-465-719-100
; Sequence 100, Application US/09465719
; Patent No. 6265377
; GENERAL INFORMATION:
; APPLICANT: Daseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION NUMBER: US/09/465,719
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/940,093
; FILING DATE: 29-SEP-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:

Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

; APPLICATION NUMBER: US/09/465,719
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION NUMBER: 08/940,093
; FILING DATE: 29-SEP-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-465-719-100

Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQK 22
Db 1 PVLDFRELLNELLEALKQK 22

RESULT 13
US-08-942-597-1
; Sequence 1, Application US/08942597
; Patent No. 6287590
; GENERAL INFORMATION:
; APPLICANT: Daseux, Jean-Louis
; TITLE OF INVENTION: PEPTIDE/LIPID COMPLEX FORMATION
; TITLE OF INVENTION: BY CO-LYOPHILIZATION
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds, LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/942,597
; FILING DATE: 02-OCT-1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 9196-0008-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-942-597-1

Query Match 100.0%; Score 105; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 PVLDFRELLNELLEALKQK 22  
Db 1 PVLDFRELLNELLEALKQK 22

## RESULT 14

US-09-453-605-4  
; Sequence 4, Application US/09453605  
; Patent No. 6329341  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; Sekul, Renate  
; Buttner, Klaus  
; Cornut, Isabelle  
; Metz, Gunther  
; Dufourcq, Jean

TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

NUMBER OF SEQUENCES: 258  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds LLP  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA

ZIP: 10036-2811  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSEQ Version 2.0  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/453.605  
FILING DATE: 26-No. 6329341-1999  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/940,095  
FILING DATE: <Unknown>

ATTORNEY/AGENT INFORMATION:  
NAME: Coruzzi, Laura A

REGISTRATION NUMBER: 30,742  
REFERENCE/DOCKET NUMBER: 009196-0004-999  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-493-4935  
TELEFAX: 650-493-5556  
TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 22 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: No. 6329341e  
SEQUENCE DESCRIPTION: SEQ ID NO: 4:

US-09-453-605-4

Query Match 100.0%; Score 105; DB 2; Length 22;  
Best Local Similarity 100.0%; Pred. No. 4.9e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQK 22  
Db 1 PVLDFRELLNELLEALKQK 22

## RESULT 15

US-09-453-605-30  
; Sequence 30, Application US/09453605  
; Patent No. 6329341  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; Sekul, Renate  
; Buttner, Klaus

?

Cornut, Isabelle  
Dufourcq, Jean  
TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS  
NUMBER OF SEQUENCES: 258  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds LLP  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA

ZIP: 10036-2811  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSEQ Version 2.0  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/453,605  
FILING DATE: 26-No. 6329341-1999  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/940,095  
FILING DATE: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Coruzzi, Laura A

REGISTRATION NUMBER: 30,742

REFERENCE/DOCKET NUMBER: 009196-0004-999

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-493-4935

TELEFAX: 650-493-5556

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 30:

SEQUENCE CHARACTERISTICS:

LENGTH: 22 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: No. 6329341e

FEATURE:

NAME/KEY: Other

LOCATION: 1...22

OTHER INFORMATION: N-terminal dansylated peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 30:

US-09-453-605-30

Query Match 100.0%; Score 105; DB 2; Length 22;  
Best Local Similarity 100.0%; Pred. No. 4.9e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQK 22  
Db 1 PVLDFRELLNELLEALKQK 22

Search completed: August 16, 2007, 22:50:33  
Job time : 74 secs

GenCore version 6.2.1  
Copyright (c) 1993 - 2007 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: August 16, 2007, 22:49:31 ; Search time 300 Seconds  
(without alignments)  
59.976 Million cell updates/sec

Title: US-10-715-895A-4  
Perfect score: 105  
Sequence: 1 PVLDFRELLNELLKQKLLK 22

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 3552611 seqs, 817857308 residues

Total number of hits satisfying chosen parameters: 3552611

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA\_Main:\*

- 1: /EMC Celerra\_SIDS2/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*
- 2: /EMC Celerra\_SIDS2/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*
- 3: /EMC Celerra\_SIDS2/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*
- 4: /EMC Celerra\_SIDS2/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*
- 5: /EMC Celerra\_SIDS2/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*
- 6: /EMC Celerra\_SIDS2/ptodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	105	100.0	22	3	US-09-865-989-4
2	105	100.0	22	3	US-09-865-989-30
3	105	100.0	22	3	US-09-865-989-100
4	105	100.0	22	3	US-09-865-989-4
5	105	100.0	22	3	US-09-865-989-30
6	105	100.0	22	3	US-09-865-989-100
7	105	100.0	22	4	US-10-099-574A-4
8	105	100.0	22	4	US-10-099-574A-30
9	105	100.0	22	4	US-10-099-574A-100
10	105	100.0	22	4	US-10-252-940-1
11	105	100.0	22	4	US-10-099-836B-4
12	105	100.0	22	4	US-10-099-836B-30
13	105	100.0	22	4	US-10-099-836B-100
14	105	100.0	22	4	US-10-283-599-4
15	105	100.0	22	4	US-10-283-599-30
16	105	100.0	22	4	US-10-283-599-100
17	105	100.0	22	4	US-10-802-080-4
18	105	100.0	22	4	US-10-802-080-30
19	105	100.0	22	4	US-10-802-080-100
20	105	100.0	22	4	US-10-801-897-4
21	105	100.0	22	4	US-10-801-897-30
22	105	100.0	22	4	US-10-801-897-100
23	105	100.0	22	5	US-10-937-767-4
24	105	100.0	22	5	US-10-937-767-30
25	105	100.0	22	5	US-10-937-767-100
26	105	100.0	22	5	US-10-991-217-4
27	105	100.0	22	5	US-10-991-217-30

28	105	100.0	22	5	US-10-991-217-100	Sequence 100, Appli
29	105	100.0	22	5	US-10-099-574A-4	Sequence 4, Appli
30	105	100.0	22	5	US-10-099-574A-30	Sequence 30, Appli
31	105	100.0	22	5	US-10-099-574A-100	Sequence 100, Appli
32	105	100.0	22	5	US-10-715-895-4	Sequence 4, Appli
33	105	100.0	22	5	US-10-715-895-30	Sequence 30, Appli
34	105	100.0	22	5	US-10-715-895-100	Sequence 100, Appli
35	105	100.0	22	6	US-11-482-292-4	Sequence 4, Appli
36	105	100.0	22	6	US-11-482-292-30	Sequence 30, Appli
37	105	100.0	22	6	US-11-482-292-100	Sequence 100, Appli
38	105	100.0	22	6	US-11-683-784-1	Sequence 1, Appli
39	102	97.1	22	3	US-09-865-989-7	Sequence 7, Appli
40	102	97.1	22	3	US-09-865-989-7	Sequence 7, Appli
41	102	97.1	22	4	US-10-099-574A-7	Sequence 7, Appli
42	102	97.1	22	4	US-10-099-836B-7	Sequence 7, Appli
43	102	97.1	22	4	US-10-283-599-7	Sequence 7, Appli
44	102	97.1	22	4	US-10-802-080-7	Sequence 7, Appli
45	102	97.1	22	4	US-10-801-897-7	Sequence 7, Appli

ALIGNMENTS

RESULT 1  
US-09-865-989-4  
; Sequence 4, Application US/09865989  
; Publication No. US2003000827A1  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; Sekul, Renate  
; Buttner, Klaus  
; Cornut, Isabelle  
; Metz, Gunther  
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
; NUMBER OF SEQUENCES: 258  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/865,989  
; FILING DATE: 25-May-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/465,719  
; FILING DATE: 17-DEC-1999  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0006-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEFAX: 650-493-5556  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 22 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: NO. US2003000827A1e  
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
US-09-865-989-4



Query Match 100.0%; Score 105; DB 3; Length 22;  
Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 22  
Db 1 PVLDLFRELLNELLEALKQK 22

## RESULT 2

US-09-865-989-30  
; Sequence 30, Application US/09865989  
; Publication No. US20030008827A1

## GENERAL INFORMATION:

APPLICANT: Dasseux, Jean-Louis  
; Sekul, Renate  
; Buttner, Klaus  
; Cornut, Isabelle  
; Metz, Gunther

## TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS

AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

NUMBER OF SEQUENCES: 258

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA

ZIP: 10036-2811

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/865,989  
; FILING DATE: 25-May-2001  
; CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/465,719

FILING DATE: 17-DEC-1999

ATTORNEY/AGENT INFORMATION:

NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0006-999

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-493-4935

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 30:

SEQUENCE CHARACTERISTICS:

LENGTH: 22 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: No. US20030008827A1e

FEATURE:

NAME/KEY: Other

LOCATION: 1...22

OTHER INFORMATION: N-terminal dansylated peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 30;

US-09-865-989-30

Query Match 100.0%; Score 105; DB 3; Length 22;

Best Local Similarity 100.0%; Pred. No. 1.8e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 22  
Db 1 PVLDLFRELLNELLEALKQK 22

## RESULT 3

US-09-865-989-4

; Sequence 4, Application US/09865989

; Publication No. US20040029807A9

GENERAL INFORMATION:

APPLICANT: Dasseux, Jean-Louis

; Sekul, Renate

; Buttner, Klaus

; Cornut, Isabelle

; Metz, Gunther

; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS

AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

NUMBER OF SEQUENCES: 258

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds LLP

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: NY

COUNTRY: USA

ZIP: 10036-2811

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSEQ Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/865,989

FILING DATE: 25-May-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/465,719

FILING DATE: 17-DEC-1999

ATTORNEY/AGENT INFORMATION:

NAME: Coruzzi, Laura A

REGISTRATION NUMBER: 30,742

REFERENCE/DOCKET NUMBER: 009196-0006-999

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-493-4935

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 100:

SEQUENCE CHARACTERISTICS:

LENGTH: 22 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: No. US20030008827A1e

FEATURE:

NAME/KEY: Other

LOCATION: 1...22

OTHER INFORMATION: All amino acids are in the D-configuration

SEQUENCE DESCRIPTION: SEQ ID NO: 100;

US-09-865-989-100

Query Match 100.0%; Score 105; DB 3; Length 22;

Best Local Similarity 100.0%; Pred. No. 1.8e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 22

Db 1 PVLDLFRELLNELLEALKQK 22

RESULT 4

US-09-865-989-4

; Sequence 4, Application US/09865989

; Publication No. US20040029807A9

GENERAL INFORMATION:

APPLICANT: Dasseux, Jean-Louis

; Sekul, Renate

; Buttner, Klaus

; Cornut, Isabelle

; Metz, Gunther

; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS

AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

NUMBER OF SEQUENCES: 258

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds LLP

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: NY

COUNTRY: USA

ZIP: 10036-2811

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSEQ Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/865,989

FILING DATE: 25-May-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/465,719

FILING DATE: 17-DEC-1999

ATTORNEY/AGENT INFORMATION:

NAME: Coruzzi, Laura A

REGISTRATION NUMBER: 30,742

REFERENCE/DOCKET NUMBER: 009196-0006-999

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-493-4935

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 100:

SEQUENCE CHARACTERISTICS:

LENGTH: 22 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: No. US20030008827A1e

FEATURE:

NAME/KEY: Other

LOCATION: 1...22

OTHER INFORMATION: All amino acids are in the D-configuration

SEQUENCE DESCRIPTION: SEQ ID NO: 100;

US-09-865-989-100

Query Match 100.0%; Score 105; DB 3; Length 22;

Best Local Similarity 100.0%; Pred. No. 1.8e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 22

Db 1 PVLDLFRELLNELLEALKQK 22

```
; AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
;
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/865,989
; FILING DATE: 25-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/465,719
; FILING DATE: 17-DEC-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. US20040029807A9e
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-865-989-4

Query Match 100.0%; Score 105; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLK 22
Db 1 PVLDFRELLNELLEALKQKLK 22

RESULT 5
US-09-865-989-30
; Sequence 30, Application US/09865989
; Publication No. US20040029807A9
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; Sekul, Renate
; Buttner, Klaus
; Cornut, Isabelle
; Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/865,989
; FILING DATE: 25-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/465,719
; FILING DATE: 17-DEC-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
```

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/865,989
; FILING DATE: 25-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/465,719
; FILING DATE: 17-DEC-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. US20040029807A9e
; FEATURES:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: N-terminal dansylated peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 30:
US-09-865-989-30

Query Match 100.0%; Score 105; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLK 22
Db 1 PVLDFRELLNELLEALKQKLK 22

RESULT 6
US-09-865-989-100
; Sequence 100, Application US/09865989
; Publication No. US20040029807A9
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; Sekul, Renate
; Buttner, Klaus
; Cornut, Isabelle
; Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 258
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/865,989
; FILING DATE: 25-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/465,719
; FILING DATE: 17-DEC-1999
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
```

```
;
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. US20040029807A9e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: All amino acids are in the D-configuration
; SEQUENCE DESCRIPTION: SEQ ID NO: 100:
US-09-865-989-100

Query Match 100.0%; Score 105; DB 3; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDLFRELLNELLKQK 22
| | | | | | | | | | | | | | | | | | | |
Db 1 PVLDLFRELLNELLKQK 22
| | | | | | | | | | | | | | | | | | | |

RESULT 7
US-10-099-574A-4
; Sequence 4, Application US/10099574A
; Publication No. US20030060604A1
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 29-SEP-1997
; CLASSIFICATION:
; PRIOR APPLICATION NUMBER:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 574A
; APPLICATION NUMBER: US/10/099,574A
; FILING DATE: 29-SEP-1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single

;
; REFERENCE/DOCKET NUMBER: 009196-0006-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. US20030060604A1e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: N-terminal dansylated peptide
US-10-099-574A-30

Query Match 100.0%; Score 105; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDLFRELLNELLKQK 22
| | | | | | | | | | | | | | | | | | | |
Db 1 PVLDLFRELLNELLKQK 22
| | | | | | | | | | | | | | | | | | | |

RESULT 8
US-10-099-574A-30
; Sequence 30, Application US/10099574A
; Publication No. US20030060604A1
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 29-SEP-1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. US20030060604A1e
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: N-terminal dansylated peptide
US-10-099-574A-30

Query Match 100.0%; Score 105; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDLFRELLNELLKQK 22
| | | | | | | | | | | | | | | | | | | |
Db 1 PVLDLFRELLNELLKQK 22
| | | | | | | | | | | | | | | | | | | |
```

```

RESULT 9
US-10-099-574A-100
; Sequence 100, Application US/10099574A
; Publication No. US20030060604A1
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; TITLE OF INVENTION: APOLIPROTEIN A-I AGONISTS
; TITLE OF INVENTION: AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/099,574A
; FILING DATE: 29-SEP-1997
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 009196-0005-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; NAME/KEY: Other
; LOCATION: 1...22
; OTHER INFORMATION: All amino acids are in the D-configuration
US-10-099-574A-100

Query Match 100.0%; Score 105; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 22
Db 1 PVLDLFRELLNELLEALKQK 22

RESULT 10
US-10-252-940-1
; Sequence 1, Application US/10252940
; Publication No. US20030099714A1
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; TITLE OF INVENTION: PEPTIDE/LIPID COMPLEX FORMATION
; BY CO-LYOPHILIZATION
; NUMBER OF SEQUENCES: 1

```

```

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds, LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSEQ for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/252,940
; FILING DATE: 23-Sep-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/942,597
; FILING DATE: 02-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 9196-0008-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-493-4935
; TELEFAX: 650-493-5556
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-252-940-1

Query Match 100.0%; Score 105; DB 4; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.8e-07;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 22
Db 1 PVLDLFRELLNELLEALKQK 22

RESULT 11
US-10-099-836B-4
; Sequence 4, Application US/10099836B
; Publication No. US20030203842A1
; GENERAL INFORMATION:
; APPLICANT: Dasseux, Jean-Louis
; APPLICANT: Sekul, Renate
; APPLICANT: Buttner, Klaus
; APPLICANT: Cornut, Isabelle
; APPLICANT: Metz, Gunther
; APPLICANT: Dufourcq, Jean
; TITLE OF INVENTION: APOLIPROTEIN A-I AGONISTS
; AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS
; NUMBER OF SEQUENCES: 254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2811
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/099,836B

```

;/ FILING DATE: 28-AUG-2002  
;/ CLASSIFICATION: <Unknown>  
;/ PRIOR APPLICATION DATA:  
;/ APPLICATION NUMBER: <Unknown>  
;/ FILING DATE: <Unknown>  
;/ ATTORNEY/AGENT INFORMATION:  
;/ NAME: Coruzzi, Laura A  
;/ REGISTRATION NUMBER: 30,742  
;/ REFERENCE/DOCKET NUMBER: 009196-0004-999  
;/ TELECOMMUNICATION INFORMATION:  
;/ TELEPHONE: 650-493-4935  
;/ TELEX: 66141 PENNIE  
;/ INFORMATION FOR SEQ ID NO: 4:  
;/ SEQUENCE CHARACTERISTICS:  
;/ LENGTH: 22 amino acids  
;/ TYPE: amino acid  
;/ STRANDEDNESS: single  
;/ TOPOLOGY: linear  
;/ MOLECULE TYPE: No. US20030203842A1e  
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
US-10-099-836B-4

Query Match 100.0%; Score 105; DB 4; Length 22;  
Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 PVLDFRELLNELLALKQK 22  
Db 1 PVLDFRELLNELLALKQK 22

RESULT 12  
US-10-099-836B-30  
; Sequence 30, Application US/10099836B  
; Publication No. US20030203842A1  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; Sekul, Renate  
; Buttner, Klaus  
; Cornut, Isabelle  
; Metz, Gunther  
; Dufourcq, Jean  
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
; AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS  
; NUMBER OF SEQUENCES: 254  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/099,836B  
; FILING DATE: 28-AUG-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: <Unknown>  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0004-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEX: 66141 PENNIE

;/ INFORMATION FOR SEQ ID NO: 30:  
;/ SEQUENCE CHARACTERISTICS:  
;/ LENGTH: 22 amino acids  
;/ TYPE: amino acid  
;/ STRANDEDNESS: single  
;/ TOPOLOGY: linear  
;/ MOLECULE TYPE: No. US20030203842A1e  
;/ FEATURE:  
;/ NAME/KEY: Other  
;/ LOCATION: 1...22  
;/ OTHER INFORMATION: N-terminal dansylated peptide  
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 30:  
US-10-099-836B-30  
Query Match 100.0%; Score 105; DB 4; Length 22;  
Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 PVLDFRELLNELLALKQK 22  
Db 1 PVLDFRELLNELLALKQK 22

RESULT 13  
US-10-099-836B-100  
; Sequence 100, Application US/10099836B  
; Publication No. US20030203842A1  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; Sekul, Renate  
; Buttner, Klaus  
; Cornut, Isabelle  
; Metz, Gunther  
; Dufourcq, Jean  
; TITLE OF INVENTION: APOLIPOPROTEIN A-I AGONISTS  
; AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS  
; NUMBER OF SEQUENCES: 254  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/099,836B  
; FILING DATE: 28-AUG-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: <Unknown>  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0004-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEX: 66141 PENNIE  
;/ INFORMATION FOR SEQ ID NO: 100:  
;/ SEQUENCE CHARACTERISTICS:  
;/ LENGTH: 22 amino acids  
;/ TYPE: amino acid  
;/ STRANDEDNESS: single  
;/ TOPOLOGY: linear  
;/ MOLECULE TYPE: No. US20030203842A1e  
;/ FEATURE:  
;/ NAME/KEY: Other

LOCATION: 1...22  
OTHER INFORMATION: All amino acids are in the D-configuration  
SEQUENCE DESCRIPTION: SEQ ID NO: 100:  
US-10-099-836B-100

Query Match 100.0%; Score 105; DB 4; Length 22;  
Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQKLIK 22  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 PVLDLFRELLNELLEALKQKLIK 22

RESULT 14  
US-10-283-599-4  
; Sequence 4, Application US/10283599  
; Publication No. US20030208059A1  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; APPLICANT: Sekul, Renate  
; APPLICANT: Buttner, Klaus  
; APPLICANT: Cornut, Isabelle  
; APPLICANT: Metz, Gunther  
; APPLICANT: Dufourcq, Jean  
; TITLE OF INVENTION: GENE THERAPY APPROACHES TO  
; TITLE OF INVENTION: SUPPLY APOLIPOPROTEIN A-I AGONISTS AND THEIR  
; TITLE OF INVENTION: USE TO TREAT DYSLIPIDEMIC DISORDERS.  
; NUMBER OF SEQUENCES: 274  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/283,599  
; FILING DATE: 29-OCT-2002  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/940,136  
; FILING DATE: 29-SEP-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0007-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEFAX: 650-493-5556  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 22 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: No. US20030208059A1  
; US-10-283-599-4

Query Match 100.0%; Score 105; DB 4; Length 22;  
Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQKLIK 22  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 PVLDLFRELLNELLEALKQKLIK 22

RESULT 15  
US-10-283-599-30  
; Sequence 30, Application US/10283599  
; Publication No. US20030208059A1  
; GENERAL INFORMATION:  
; APPLICANT: Dasseux, Jean-Louis  
; APPLICANT: Sekul, Renate  
; APPLICANT: Buttner, Klaus  
; APPLICANT: Cornut, Isabelle  
; APPLICANT: Metz, Gunther  
; APPLICANT: Dufourcq, Jean  
; TITLE OF INVENTION: GENE THERAPY APPROACHES TO  
; TITLE OF INVENTION: SUPPLY APOLIPOPROTEIN A-I AGONISTS AND THEIR  
; TITLE OF INVENTION: USE TO TREAT DYSLIPIDEMIC DISORDERS.  
; NUMBER OF SEQUENCES: 274  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Pennie & Edmonds LLP  
; STREET: 1155 Avenue of the Americas  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036-2811  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/283,599  
; FILING DATE: 29-OCT-2002  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/940,136  
; FILING DATE: 29-SEP-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Coruzzi, Laura A  
; REGISTRATION NUMBER: 30,742  
; REFERENCE/DOCKET NUMBER: 009196-0007-999  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-493-4935  
; TELEFAX: 650-493-5556  
; TELEX: 66141 PENNIE  
; INFORMATION FOR SEQ ID NO: 30:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 22 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: No. US20030208059A1  
; FEATURE:  
; NAME/KEY: Other  
; LOCATION: 1...22  
; OTHER INFORMATION: N-terminal dansylated peptide  
; US-10-283-599-30

Query Match 100.0%; Score 105; DB 4; Length 22;  
Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQKLIK 22  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 PVLDLFRELLNELLEALKQKLIK 22

Search completed: August 16, 2007, 22:55:39  
Job time : 301 secs

November 2005

Published\_Applications Nucleic Acid and Published\_Applications Amino Acid database searches now generate two sets of results each. The Published\_Applications databases have been split into two parts to reduce the amount of time required for their daily updates. This results in more machine time being available for processing searches.

Newly published applications will appear in the Published\_Applications\_New databases; older published applications make up the Published\_Applications\_Main databases.

Searches run against Nucleic Acid Published\_Applications produce two sets of results, with the extensions **.rnpbm** (Published\_Applications\_NA\_Main) and **.rnpbn** (Published\_Applications\_NA\_New). Searches run against Amino Acid Published\_Applications produce two sets of results, with the extensions **.rapbm** (Published\_Applications\_AA\_Main) and **.rapbn** (Published\_Applications\_AA\_New).

---

GenCore version 6.2.1  
Copyright (c) 1993 - 2007 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: August 16, 2007, 22:50:51 ; Search time 7 Seconds  
(without alignments)  
3.121 Million cell updates/sec

Title: US-10-715-895A-4  
Perfect score: 105  
Sequence: 1 PVDLFRLLNELLKALKOKLK 22

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 5387 seqs, 993155 residues

Total number of hits satisfying chosen parameters: 5387

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA New:  
1: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US10\_NEW\_PUB.psp:  
2: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US06\_NEW\_PUB.psp:  
3: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US07\_NEW\_PUB.psp:  
4: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US08\_NEW\_PUB.psp:  
5: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US09\_NEW\_PUB.psp:  
6: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US11\_NEW\_PUB.psp:  
7: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US11\_NEW\_PUB.psp:  
8: /EMC\_Celerra\_SIDS2/ptodata/1/pubpaa/US60\_NEW\_PUB.psp:

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	41	39.0	900	1	US-10-533-069-1050
2	39	37.1	2000	1	US-10-533-069-452
3	38	36.2	154	1	US-10-533-069-1216
4	38	36.2	232	1	US-10-533-069-2353
5	38	36.2	1154	1	US-10-533-069-1039
6	37.5	35.7	1132	1	US-10-533-069-1070
7	37	35.2	508	1	US-10-533-069-432
8	37	35.2	1427	1	US-10-533-069-1043
9	36	34.3	461	1	US-10-533-069-1242
10	36	34.3	491	1	US-10-533-069-1156
11	36	34.3	491	1	US-10-533-069-1158
12	36	34.3	997	1	US-10-533-069-565
13	35.5	33.8	1220	1	US-10-533-069-141
14	35.5	33.8	1359	7	US-11-657-3113-3
15	35.5	33.8	2030	7	US-11-657-3113-24
16	35	33.3	553	7	US-11-725-235-116
17	34.5	32.9	1333	7	US-11-657-3113-23
18	34	32.4	325	1	US-10-533-069-1316
19	34	32.4	544	1	US-10-533-069-121
20	34	32.4	1097	1	US-10-533-069-943
21	34	32.4	1440	1	US-10-533-069-100
22	33.5	31.9	373	7	US-11-539-856-23
23	33.5	31.9	373	7	US-11-539-856-31
24	33.5	31.9	431	7	US-11-725-235-192
25	33.5	31.9	467	7	US-11-725-235-170

26	33.5	31.9	815	7	US-11-551-744-236
27	33.5	31.9	1647	1	US-10-533-069-735
28	33.5	31.9	2000	1	US-10-533-069-860
29	33.5	31.9	2000	1	US-10-533-069-1015
30	33.5	31.9	2022	7	US-11-551-744-292
31	33.5	31.9	3433	1	US-10-533-069-1600
32	33	31.4	333	1	US-10-533-069-725
33	33	31.4	378	1	US-10-533-069-855
34	33	31.4	511	1	US-10-533-069-1288
35	33	31.4	560	1	US-10-533-069-1172
36	33	31.4	608	1	US-10-523-312A-9
37	33	31.4	608	1	US-10-523-312A-10
38	33	31.4	808	1	US-10-533-069-1976
39	33	31.4	1960	7	US-11-656-389-74
40	33	31.4	1961	7	US-11-656-389-15
41	33	31.4	2505	7	US-11-656-389-3
42	32.5	31.0	256	1	US-10-533-069-1182
43	32.5	31.0	342	7	US-11-711-935-1
44	32.5	31.0	1396	1	US-10-533-069-707
45	32.5	31.0	2000	1	US-10-533-069-2

## ALIGNMENTS

RESULT 1  
US-10-533-069-1050  
; Sequence 1050, Application US/10533069  
; Publication No. US20070185017A1  
; GENERAL INFORMATION:  
; APPLICANT: AGGARWAL, SUDEEPTA  
; APPLICANT: CLARK, HILARY  
; APPLICANT: GURNEY, AUSTIN L.  
; APPLICANT: SCHOENFELD, JILL  
; APPLICANT: WILLIAMS, P. MICKEY  
; APPLICANT: WOOD, WILLIAM I.  
; APPLICANT: WU, THOMAS D.

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE  
; FILE REFERENCE: P1982R1 US  
; CURRENT APPLICATION NUMBER: US/10/533,069  
; PRIOR FILING DATE: 2005-04-28  
; PRIOR APPLICATION NUMBER: PCT/US03/34381  
; PRIOR FILING DATE: 2003-10-28  
; PRIOR APPLICATION NUMBER: US 60/422,472  
; PRIOR FILING DATE: 2002-10-29  
; NUMBER OF SEQ ID NOS: 2442  
; SEQ ID NO 1050  
; LENGTH: 900  
; TYPE: PRT  
; ORGANISM: Homo sapien  
US-10-533-069-1050

Query Match 39.0%; Score 41; DB 1; Length 900;  
Best Local Similarity 42.1%; Pred. No. 13;  
Matches 8; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

Qy 2 VLDLFRLLNELLKALKOK 20  
Db 798 VSPFLFKLENDQIESLRQR 816

RESULT 2  
US-10-533-069-452  
; Sequence 452, Application US/10533069  
; Publication No. US20070185017A1  
; GENERAL INFORMATION:  
; APPLICANT: AGGARWAL, SUDEEPTA  
; APPLICANT: CLARK, HILARY  
; APPLICANT: GURNEY, AUSTIN L.  
; APPLICANT: SCHOENFELD, JILL  
; APPLICANT: WILLIAMS, P. MICKEY  
; APPLICANT: WOOD, WILLIAM I.





```

; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD, WILLIAM I.
; APPLICANT: WU, THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; TITLE OF INVENTION: RELATED DISEASES
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; PRIOR FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 1070
; LENGTH: 1132
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-1070

Query Match      35.7%; Score 37.5; DB 1; Length 1132;
Best Local Similarity 39.4%; Pred. No. 54;
Matches 13; Conservative 4; Mismatches 3; Indels 13; Gaps 2;

Qy      2 VLDLFRLL-----NE-LLEALKQKL 21
Db      612 LLOBFRELLQYRDNDSKTLLEANMLLEKLRQRI 644

RESULT 7
US-10-533-069-432
; Sequence 432, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL, SUDEEPTA
; APPLICANT: CLARK, HILARY
; APPLICANT: GURNEY, AUSTIN L.
; APPLICANT: SCHOENFELD, JILL
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD, WILLIAM I.
; APPLICANT: WU, THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; TITLE OF INVENTION: RELATED DISEASES
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 432
; LENGTH: 508
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-432

Query Match      35.2%; Score 37; DB 1; Length 508;
Best Local Similarity 40.9%; Pred. No. 25;
Matches 9; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

Qy      1 PVLDFRELLNELLEALKQKL 22
Db      149 PTLDKVLELQPEKLELINDENK 170

RESULT 8
US-10-533-069-1043
; Sequence 1043, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL, SUDEEPTA
; APPLICANT: CLARK, HILARY
; APPLICANT: GURNEY, AUSTIN L.
; APPLICANT: WU, THOMAS D.
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD, WILLIAM I.
; APPLICANT: WU, THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; TITLE OF INVENTION: RELATED DISEASES
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 1043
; LENGTH: 1427
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-1043

Query Match      35.2%; Score 37; DB 1; Length 1427;
Best Local Similarity 42.9%; Pred. No. 83;
Matches 9; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

Qy      2 VLDLFRLLNELLEALKQKL 22
Db      1381 VAEIVKELRCLELQLODKIK 1401

RESULT 9
US-10-533-069-1242
; Sequence 1242, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL, SUDEEPTA
; APPLICANT: CLARK, HILARY
; APPLICANT: GURNEY, AUSTIN L.
; APPLICANT: SCHOENFELD, JILL
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD, WILLIAM I.
; APPLICANT: WU, THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; TITLE OF INVENTION: RELATED DISEASES
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 1242
; LENGTH: 461
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-1242

Query Match      34.3%; Score 36; DB 1; Length 461;
Best Local Similarity 50.0%; Pred. No. 31;
Matches 8; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy      5 LFRLLNELLEALKQK 20
Db      121 LMRVNLSESLKVLKMQ 136

RESULT 10
US-10-533-069-1156
; Sequence 1156, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL, SUDEEPTA
; APPLICANT: CLARK, HILARY

```

```

; APPLICANT: GURNEY,AUSTIN L.
; APPLICANT: SCHOENFELD,JILL
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD,WILLIAM I.
; APPLICANT: WU,THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 1156
; LENGTH: 491
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-1156

```

```

Query Match      34.3%; Score 36; DB 1; Length 491;
Best Local Similarity 50.0%; Pred. No. 34;
Matches 6; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 10 LNELLEALKQKL 21
Db 361 LQEIIVEGKQKM 372

```

```

RESULT 11
US-10-533-069-1158
; Sequence 1158, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL,SUDEEPTA
; APPLICANT: CLARK,HILARY
; APPLICANT: GURNEY,AUSTIN L.
; APPLICANT: SCHOENFELD,JILL
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD,WILLIAM I.
; APPLICANT: WU,THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 1158
; LENGTH: 491
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-1158

```

```

Query Match      34.3%; Score 36; DB 1; Length 491;
Best Local Similarity 50.0%; Pred. No. 34;
Matches 6; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 10 LNELLEALKQKL 21
Db 361 LQEIIVEGKQKM 372

```

```

RESULT 12
US-10-533-069-565
; Sequence 565, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL,SUDEEPTA

```

```

; APPLICANT: CLARK,HILARY
; APPLICANT: GURNEY,AUSTIN L.
; APPLICANT: SCHOENFELD,JILL
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD,WILLIAM I.
; APPLICANT: WU,THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 565
; LENGTH: 997
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-565

```

```

Query Match      34.3%; Score 36; DB 1; Length 997;
Best Local Similarity 43.8%; Pred. No. 76;
Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

```

```

Qy 4 DLFRELLNELLEALKQ 19
Db 941 DLLKNAXNEAIENMKQ 956

```

```

RESULT 13
US-10-533-069-141
; Sequence 141, Application US/10533069
; Publication No. US20070185017A1
; GENERAL INFORMATION:
; APPLICANT: AGGARWAL,SUDEEPTA
; APPLICANT: CLARK,HILARY
; APPLICANT: GURNEY,AUSTIN L.
; APPLICANT: SCHOENFELD,JILL
; APPLICANT: WILLIAMS, P. MICKEY
; APPLICANT: WOOD,WILLIAM I.
; APPLICANT: WU,THOMAS D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE
; FILE REFERENCE: P1982R1 US
; CURRENT APPLICATION NUMBER: US/10/533,069
; CURRENT FILING DATE: 2005-04-28
; PRIOR APPLICATION NUMBER: PCT/US03/34381
; PRIOR FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: US 60/422,472
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 2442
; SEQ ID NO 141
; LENGTH: 1220
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-533-069-141

```

```

Query Match      33.8%; Score 35.5; DB 1; Length 1220;
Best Local Similarity 38.5%; Pred. No. 1.1e+02;
Matches 10; Conservative 5; Mismatches 6; Indels 5; Gaps 1;

```

```

Qy 1 PVLDFRE-----LNLLELEALKQKL 21
Db 946 PLLVAYKDEIPVLKDELIHLEKQFL 971

```

```

RESULT 14
US-11-657-313-3
; Sequence 3, Application US/11657313
; Publication No. US20070186295A1
; GENERAL INFORMATION:

```

Search completed: August 16, 2007, 22:55:51  
Job time : 7 secs

## Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

**When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.**

---

GenCore version 6.2.1  
Copyright (c) 1993 - 2007 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: August 16, 2007, 22:39:00 ; Search time 347 Seconds  
(without alignments) 67.973 Million cell updates

Title: US-10-715-895A-4  
Perfect score: 105  
Sequence: 1 PVLDLFRELLNELLEALKQK 22

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 3281787 seqs, 1072124677 residues  
Total number of hits satisfying chosen parameters:

```

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                  Maximum Match 10%
                  Listing first 45

```

```
Database :      UniProt_8.4:*
            1: uniprot_sprot:*
            2: uniprot_trembl:
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description	
1	57	54.3	1012	2	Q6BNM5	DRBHA	Q6bnm5
2	55	52.4	892	2	Q3MCF8	ANAVT	Q3mcf8
3	54.5	51.9	216	2	Q65PC9	BACLD	Q65pc9
4						Q09054	RAT
5	53	50.5	258	2	Q08877	RAT	Q08877
6	53	50.5	259	1	AP0A1	RAT	Q04639
7	53	50.5	259	1	Q5BBB2	RAT	Q5ebb2
8	53	50.5	274	1	Y1457	LISMO	P67195
9	53	50.5	274	1	Y1476	LISNP	Q71z13
10	53	50.5	274	1	Y1494	LISIN	P67196
11	53	50.5	274	2	Q4EGJ5	LISMO	Q4egj5
12	53	50.5	274	2	Q4ETW3	LISMO	Q4etw3
13	53	50.5	280	2	Q3X8F1	PSEPF	Q3k8f1
14	53	50.5	605	2	Q2BAJ7	98ACI	Q2bai7
15	53	50.5	727	2	Q9FZ15	ARATH	Q9fz15
16	53	50.5	876	2	Q9C622	ARATH	Q9c622
17	52	49.5	224	2	Q5L430	GEOKA	Q5l430
18	52	49.5	969	2	Q5T778	ANOGA	Q5t778
19	52	49.5	1125	2	Q23YAB	TEYTH	Q23yab
20	51	48.6	148	2	Q1VMR9	9PLAO	Q1vmr9
21	51	48.6	366	2	Q93601	CHICK	Q93601
22	51	48.6	577	1	POF3	SCHPO	Q74991
23	50	47.6	277	2	Q895Y6	PSESM	Q895y6
24	50	47.6	301	2	Q6A254	HABIN	Q6a254
25	50	47.6	315	2	Q3KPO9	XENLA	Q3kpo9
26	50	47.6	317	2	Q4OPB0	HAB18	Q4opb0
27	49.5	47.1	261	2	Q25240	LEICH	Q25240
28	49	46.7	779	2	Q6Z526	ORVSA	Q6z526
29	49.5	47.1	779	2	Q22N68	TEYTH	Q22n68
30	49	46.7	86	1	Y1679	CLOAB	Q97192
31	49	46.7	995	1	CA036	HUMAN	Q7z322

## RESULT 1

Q6BNN5_DEBHA	PRELIMINARY; PRT; 1012 AA.
ID	Q6BNN5_DEBHA
AC	Q6BNN5;
DT	16-AUG-2004, integrated into UniProtKB/TrEMBL.
DT	16-AUG-2004, sequence version 1.
DT	16-AUG-2004, entry version 11.
DT	07-FEB-2006, entry version 11.
DE	Debaryomyces hansenii chromosome E of strain CBS767 of Debaryomyces hansenii.
DE	Debaryomyces hansenii
GN	OrderedLocusNames=DEHA0E21714g;
OS	Debaryomyces hansenii (Torulaspora hansenii).
OC	Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC	Saccharomycetales; Saccharomycetaceae; Debaryomycetes.
OX	NCBI TaxID:4959;

RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].

RE NUCLEOTIDE SEQUENCE (LARGE SCALE GENOMIC  
 RC STRAIN=ATCC 36239 / CBS 767;  
 RX PubMed=15229592; DOI=10.1038/nature02579;

RA Dujon B., Sherman D., Fischer G., Durrrens  
PubMed=13229392; DOI=10.1038/nature02373

RA Lafontaine I., de Montigny J., Marck C.,  
RA Goffard N., Frangeul L., Aigle M., Anthou

RA Barnay S., Blanchin S., Beckerich J.-M.,  
RA Boisrame A., Boyer J., Cattolico L., Conf

RA Despons L., Fabre E., Fairhead C., Ferry-  
Hantraye F., Hennequin C., Jauniaux N., J

RA Hantraye F., Hennequin C., Jaumiaux N., Lesur  
RA Kerrest A., Koszul R., Lemaire M., Lesur

RA Nicaud J.-M., Nikolski M., Oztas S., Ozle  
RA Pellenz S., Potier S., Richard G.-F., Str

RA Swennen D., Tekai F., Wesolowski-Louvel  
RA Zeniou-Meyer M., Zivanovic Y., Bolotin-Fu

RA Bouchier C., Caudron B., Scarpelli C., Gaudin  
RA Wincker P., Souciet J.-L.;

Wincker P., Souciet J.-L.;  
"Genome evolution in yeasts." ;

RL Nature 430:35-44 (2004).  
CC -----

CC Copyrighted by the UniProt Consortium, see  
CC Distributed under the Creative Commons At

EMBL: CP382127; CAC889468 1. -; Genomic DNA

DR EMBL; CR382137; CAG88468.1; -; Genomic DNA  
DR GO; GO:0003723; F:RNA binding; IEA.

DR InterPro; IPR003890; IF\_eIF4G.  
DR Pfam; PF02854; MIF4G; 2.

DR SMART; SM00543; MIF4G; 1.  
KW Complete proteome.

NW	Complete procedure.	
SQ	SEQUENCE	1012 AA; 118240 MW; 668882FP3

Query Match	Score 57; D
54.3%	Score 57; D

Best Local Similarity 58.8%; Pred. No. 1.  
Matches 10; Conservative 5; Mismatches

6 FREILNELLEALKOKLK 22

QY 6 FRELLNELEALKQLK 22  
:  
::|::|||  
523 WKXNMTMFTY KOWT V 529

Db 522 YKALNMEMI<sup>LL</sup>KQ<sup>KL</sup>K 538

```

RESULT 2
Q3MCF8 ANAVT
ID Q3MCF8 ANAVT PRELIMINARY; PRT; 892 AA.
AC Q3MCF8;
DT 25-OCT-2005, integrated into UniProtKB/TrEMBL.
DT 25-OCT-2005, sequence version 1.
DT 02-MAY-2006, entry version 6.
DE Hypothetical protein.
GN OrderedLocNames=Ava_1706;
OS Anabaena variabilis (strain ATCC 29413 / PCC 7937).
SC Bacteria; Cyanobacteria; Nostocales; Nostocaceae; Anabaena.
OX NCBI_TaxID=240292;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Copeland A., Lucas S., Lapidus A., Barry K., Glavina T.,
RA Hammon N., Ierani S., Pitluck S., Saunders E.H., Schmutz J.,
RA Larimer P., Land M., Kyrpides N., Mavromatis K., Richardson P.,
RT "Complete sequence of Anabaena variabilis ATCC 29413."
RL Submitted (SEP-2005) to the EMBL/GenBank/DBJ databases.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
DR EMBL; CP000117; ABA21328.1; -; Genomic_DNA.
DR GenomeReviews; CP000117_GR; Ava_1706.
DR InterPro; IPR010989; t-snare.
KW Complete proteome; Hypothetical protein.
SQ SEQUENCE 892 AA; 104914 MW; 456FIAD7C0451004 CRC64;

Query Match 52.4%; Score 55; DB 2; Length 892;
Best Local Similarity 62.5%; Pred. No. 2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 4 DLRFNELLLEALKQ 19
Db 390 DLRFNELLLEALKQ 405

RESULT 3
Q65PC9 BACLD
ID Q65PC9 BACLD PRELIMINARY; PRT; 216 AA.
AC Q65PC9; Q62ZK7;
DT 25-OCT-2004, integrated into UniProtKB/TrEMBL.
DT 25-OCT-2004, sequence version 1.
DT 27-JUN-2006, entry version 20.
DE CysE (Serine acetyltransferase).
GN Name=CysE; OrderedLocNames=BL03268, BLi00111;
OS Bacillus licheniformis (strain DSM 13 / ATCC 14580).
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=279010;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15383718; DOI=10.1186/gb-2004-5-10-r77;
RA Veith B., Herzberg C., Steckel S., Feesche J., Maurer K.H.,
RA Ehrenreich P., Baumer S., Henne A., Liesegang H., Merkl R.,
RA Ehrenreich A., Gottschalk G.;
RT "The complete genome sequence of Bacillus licheniformis DSM13, an
RT organism with great industrial potential."
RL J. Mol. Microbiol. Biotechnol. 7:204-211(2004).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15461803; DOI=10.1186/gb-2004-5-10-r77;
RA Rev M.W., Ramaiva P., Nelson B.A., Brody-Karpin S.D., Zaretsky E.J.,
RA Tang M., Lopez de Leon A., Xiang H., Gusti V., Clausen I.G.,
RA Olsen P.B., Rasmussen M.D., Andersen J.T., Joergensen P.D.,
RA Larsen T.S., Sorokan A., Bolotin A., Lapidus A., Galleron N.,
RA Ehrlich S.D., Berka R.M.;
RT "Complete genome sequence of the industrial bacterium Bacillus
RT licheniformis and comparisons with closely related Bacillus species."
RL Genome Biol. 5:RESEARCH077.1-RESEARCH077.12(2004).
CC -!- CATALYTIC ACTIVITY: Acetyl-CoA + L-serine = CoA + O-acetyl-L-
serine.

```

```

CC -!- PATHWAY: Cysteine biosynthesis.
CC -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity).
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
DR EMBL; AE017333; AAU39085.1; -; Genomic_DNA.
DR EMBL; CP000002; AAU21741.1; -; Genomic_DNA.
DR GenomeReviews; CP000002_GR; BL03268.
DR GenomeReviews; AE017333_GR; BLi00111.
DR GO; GO:0005737; C:cytoplasm; IEA.
DR GO; GO:0009001; F:serine O-acetyltransferase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR GO; GO:0006535; P:cysteine biosynthesis from serine; IEA.
DR InterPro; IPR005881; CysE transferase.
DR InterPro; IPR001451; Hexapep transf.
DR InterPro; IPR011004; Trimer_LpxA_like.
DR Pfam; PF00132; Hexapep; 4.
DR TIGRfams; TIGR01172; CysE; 1.
KW Acyltransferase; Amino-acid biosynthesis; Complete proteome;
KW Cysteine biosynthesis; Repeat; Transferase.
SQ SEQUENCE 216 AA; 24124 MW; 4CIAD0CC51F74B4C CRC64;

Query Match 51.9%; Score 54.5; DB 2; Length 216;
Best Local Similarity 59.1%; Pred. No. 61;
Matches 13; Conservative 4; Mismatches 4; Indels 1; Gaps 1;

OY 1 PVLDLRFNELLLEALKQ 22
Db 188 PVADRFRELENEIRQ-LKQELR 208

RESULT 4
O09054 RAT
ID O09054 RAT PRELIMINARY; PRT; 258 AA.
AC O09054;
DT 01-JUL-1997, integrated into UniProtKB/TrEMBL.
DT 01-JUL-1997, sequence version 1.
DT 27-JUN-2006, entry version 25.
DE Apolipoprotein A-I.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=WKY, and SHRSP; TISSUE=Spleen;
RX MEDLINE=98077648; PubMed=9415807;
RA Chiang A.N., Fan K.C., Shaw G.C., Yang U.C.;
RT "Repetitive elements in the third intron of murine apolipoprotein A-I
RT gene."
RL Biochem. Mol. Biol. Int. 43:989-996(1997).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=WKY, and SHRSP; TISSUE=Spleen;
RA Chiang A.N., Fan K.C., Shaw G.C., Yang U.C.;
RL Submitted (NOV-1996) to the EMBL/GenBank/DBJ databases.
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
-----
DR EMBL; U79578; AAB58430.1; -; Genomic_DNA.
DR EMBL; U79577; AAB58429.1; -; Genomic_DNA.
DR HSPF; P02477; IAV1.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0008289; F:lipid transport; IEA.
DR GO; GO:0006869; F:lipid transport; IEA.
DR GO; GO:0042157; P:lipoprotein metabolism; IEA.
DR InterPro; IPR013326; ApoA/E_ApoLp.
DR InterPro; IPR000074; ApoA1_A4_E.
DR Pfam; PF01442; Apolipoprotein; 1.
KW Lipoprotein.

```

Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
Muroidea; Muridae; Murinae; Rattus.  
NCBI\_TaxID=10116;  
[1]  
NUCLEOTIDE SEQUENCE.  
MEDLINE=84207987; PubMed=6426956;  
Poncin J.E., Martial J.A., Gielen J.E.;  
"Cloning and structure analysis of the rat apolipoprotein A-I CDNA.";  
Eur. J. Biochem. 140:493-498(1984).  
[2]  
NUCLEOTIDE SEQUENCE.  
MEDLINE=87008540; PubMed=3020028;  
Haddad I.A., Ordovas J.M., Fitzpatrick T., Karathanasis S.K.;  
"Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes";  
J. Biol. Chem. 261:13268-13277(1986).  
[3]  
PROTEIN SEQUENCE OF 1-45.  
STRAIN=Sprague-Dawley;  
MEDLINE=82098162; PubMed=6798036;  
Gordon J.I., Smith D.P., Andy R., Alpers D.H., Schonfeld G., Strauss A.W.;  
"The primary translation product of rat intestinal apolipoprotein A-I mRNA is an unusual preproprotein.";  
J. Biol. Chem. 257:971-978(1982).  
-!- FUNCTION: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT).  
-!- SUBCELLULAR LOCATION: Secreted protein.  
-!- TISSUE SPECIFICITY: Major protein of plasma HDL, also found in chylomicrons.  
-!- SIMILARITY: Belongs to the apolipoprotein AI/A4/E family.  
-----  
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms  
Distributed under the Creative Commons Attribution-NoDerivs License  
-----  
EMBL: M00001; AAA40749.1; -; mRNA.  
EMBL: X00558; CAA25224.1; -; mRNA.  
EMBL: J02597; AAA40745.1; -; Genomic\_DNA.  
PIR: A24700; A24700.  
HSSP: P02647; LAVI.  
GO: 2130; Apoa1.  
GO: GO:0017127; F:cholesterol transporter activity; IDA.  
GO: GO:0005548; F:phospholipid transporter activity; IDA.  
GO: GO:0030301; P:cholesterol transport; IDA.  
GO: GO:0015914; P:phospholipid transport; IDA.  
InterPro: IPRO13326; ApoA/E\_Apolp.  
InterPro: IPR000074; ApoA1\_A4\_E.  
Pfam: PF01442; Apolipoprotein; 1.  
Cholesterol metabolism; Direct protein sequencing; HDL;  
Lipid metabolism; Lipid transport; Repeat; Signal; Steroid metabolism;  
Transport.  
SIGNALL 1 18  
PROPEP 19 24  
CHAIN 25 259 /FTId=PRO\_0000001953.  
APOLIPOPROTEIN A-I.  
/FTId=PRO\_0000001954.  
REPEAT 67 88 1.  
REPEAT 89 110 2.  
REPEAT 111 121 3;  
REPEAT 122 143 4;  
REPEAT 144 161 5;  
REPEAT 162 183 6;  
REPEAT 184 203 7;  
REPEAT 204 225 8;  
REPEAT 226 236 9;  
REPEAT 237 259 10.  
REGION 67 259 10 X approximate tandem repeats.  
CONFLICT 201 201 R -> K (in Ref. 2).  
CONFLICT 214 214 G -> S (in Ref. 2).  
CONFLICT 218 218 R -> K (in Ref. 2).  
SEQUENCE 259 AA; Q30088 MW; 2E8D5EB45FEAE88 CRC64;



Query Match 50.5%; Score 53; DB 1; Length 259;  
 Best Local Similarity 54.5%; Pred. No. 1.1e+02;  
 Matches 12; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 PVLDLFRLLNLEALKOKLK 22  
 DB 122 PHLDFEQKWEVEAYRQKLE 143

RESULT 7  
 Q5EBB2\_RAT PRELIMINARY; PRT; 259 AA.  
 ID Q5EBB2;  
 AC Q5EBB2;

DT 10-MAY-2005, integrated into UniProtKB/TrEMBL.  
 DT 10-MAY-2005, sequence version 1.  
 DT 27-JUN-2006, entry version 6.

DE Apolipoprotein A-I.

GN Name=ApoA1;

OS Rattus norvegicus (Rat).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

OC Muridea; Muridae; Murinae; Rattus.

OC NCBI\_TaxID=10116;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Liver;

RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Ioquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,

RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalusz D.E.,

RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;

RT "Generation and initial analysis of more than 15,000 full-length human

and mouse cDNA sequences.";

RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).

RL [2]

RN NUCLEOTIDE SEQUENCE.

RC TISSUE=Liver;

RA Director MGC Project;

RA Submitted (FEB-2005) to the EMBL/GenBank/DBJ databases.

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----

CC -----

CC -----

CC -----

DR EMBL; BC089820; AAH89820.1; -; mRNA.

DR UniGene; Rn.10308; -;

DR GO; GO:0005576; C:extracellular region; IEA.

DR GO; GO:0008289; F:lipid binding; IEA.

DR GO; GO:0006869; P:lipid transport; IEA.

DR GO; GO:0042157; P:lipoprotein metabolism; IEA.

DR InterPro; IPR013326; ApoA1/ApoLp.

DR InterPro; IPR000074; ApoA1/A4\_E.

DR Pfam; PF01442; Apolipoprotein; 1.

KW Lipoprotein.

SQ SEQUENCE 259 AA; 30062 MW; 28538891B2E3A6CD CRC64;

Query Match 50.5%; Score 53; DB 2; Length 259;

Best Local Similarity 54.5%; Pred. No. 1.1e+02;

Matches 12; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 PVLDLFRLLNLEALKOKLK 22  
 DB 122 PHLDFEQKWEVEAYRQKLE 143

RESULT 8  
 Y1457\_LISMO STANDARD; PRT; 274 AA.  
 ID Y1457\_LISMO  
 AC P67195; Q92BQ3;

DT 11-OCT-2004, integrated into UniProtKB/Swiss-Prot.

DT 11-OCT-2004, sequence version 1.

DT 30-MAY-2006, entry version 9.

DE UPF0085 protein lmo1457;

GN OrderedLocNames=lmo1457;

OS Listeria monocytogenes.

OC Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.

OC NCBI\_TaxID=1639;

RN [1]

RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].

RC STRAIN=ATCC BAA-679 / EGD-e / Serovar 1/2a;

RX MEDLINE=21537279; PubMed=11679669; DOI=10.1126/science.1063447;

RA Glaser P., Frangeul L., Buchrieser C., Rusniok C., Amend A.,

RA Baquero F., Berche P., Bloeker H., Brandt P., Chakraborty T.,

RA Charbit A., Chetouani F., Couve E., de Daruvar A., Dehoux P.,

RA Domann E., Dominguez-Bernal G., Duchaud E., Durant L., Dussurget O.,

RA Entian K.-D., Feihl H., Garcia-del Portillo F., Garrido P.,

RA Gautier L., Goebel W., Gomez-Lopez N., Hain T., Hauf J., Jackson D.,

RA Jones L.-M., Kaerst U., Krest J., Kuhn M., Kunst F., Kurapkat G.,

RA Madueno E., Maitournan A., Mata Vicente J., Ng E., Nedjari H.,

RA Nordsiek G., Novella S., de Pablos B., Perez-Diaz J.-C., Purcell R.,

RA Remmel B., Rose M., Schlueter T., Simoes N., Tierrez A.,

RA Vazquez-Boland J.-A., Voss H., Weiland J., Cossart P.,

RT "Comparative genomics of Listeria species.";

RL Science 294:849-852 (2001).

CC -1- SIMILARITY: Belongs to the UPF0085 family.

CC -----

CC -----

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----

CC -----

DR EMBL; AL591979; CAC959535.1; -; Genomic DNA.

DR PIR; A11256; A11256

DR GenomeReviews; AL591824\_GR; lmo1457.

DR ListList; LMO01457; -;

DR LinkHub; P67195; -;

DR HAMAP; MF\_01062; -; 1.

DR InterPro; IPR005177; DUF299.

DR Pfam; PF03618; DUF299; 1.

DR ATP-binding; Complete proteome; Nucleotide-binding.

FT CHAIN 1 274 UPF0085 protein lmo1457.

FT NP BIND 149 156 /FTID=PRO\_0000196674.

FT SEQUENCE 274 AA; 30436 MW; A149AF0F8D5D1B1A CRC64;

Query Match 50.5%; Score 53; DB 1; Length 274;

Best Local Similarity 55.0%; Pred. No. 1.2e+02;

Matches 11; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 PVLDLFRLLNLEALKOK 20

DB 84 PIIILFGPLNQLQETKIK 103

RESULT 9

Y1476\_LISMF STANDARD; PRT; 274 AA.

ID Y1476\_LISMF

AC Q71ZL3;

DT 30-JUL-2004, integrated into UniProtKB/Swiss-Prot.

DT 05-JUL-2004, sequence version 1.

DT 07-MAR-2006, entry version 15.

DE UPF0085 protein LMOF2365 1476.

GN OrderedLocNames=LMOF2365\_1476;

OS Listeria monocytogenes serotype 4b (strain F2365).

OC Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.



```
RESULT 12
Q4ETW3_LISMO PRELIMINARY; PRT; 274 AA.
ID Q4ETW3_LISMO
AC Q4ETW3;
DT 13-SEP-2005, integrated into UniProtKB/TrEMBL.
DT 13-SEP-2005, sequence version 1.
DT 18-APR-2006, entry version 3.
DE Hypothetical protein.
GN ORFNames=LMOF6854_1500;
OS Listeria monocytogenes str. 1/2a F6854.
OC Bacteria; Firmicutes; Bacillales; Listeriaceae; Listeria.
OX NCBI_TaxID=267409;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=1/2a F6854;
RX PubMed=15115801; DOI=10.1093/nar/gkh562;
RA Nelson K.E., Fouts D.E., Mongodin E.F., Ravel J., DeBoy R.T.,
RA Kolonay J.F., Rasko D.A., Anguoli S.V., Gill S.R., Paulsen I.T.,
RA Peterson J.D., White O., Nelson W.C., Nierman W.C., Beanan M.J.,
RA Brinkac L.M., Daugherty S.C., Dodson R.J., Durkin A.S., Madupu R.,
RA Haft D.H., Selengut J., Van Aken S.E., Khouri H.M., Fedorova N.,
RA Forbester H.A., Tran B., Kathariou S., Wonderling L.D., Uhlrich G.A.,
RA Bayles D.O., Luchansky J.B., Fraser C.M.;
RT "Whole genome comparisons of serotype 4b and 1/2a strains of the food-
RT borne pathogen Listeria monocytogenes reveal new insights into the
RT core genome components of this species.";
RL Nucleic Acids Res. 32:2386-2395(2004).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
CC
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC
CC EMBL; AAOQ0100006; EAL07152.1; -; Genomic_DNA.
DR InterPro; IPR005177; DUF299.
DR Pfam; PF03618; DUF299; 1.
DR Hypothetical protein.
KW SEQUENCE 274 AA; 30436 MW; A149AF0F8D5D1B1A CRC64;
Query Match 50.5%; Score 53; DB 2; Length 274;
Best Local Similarity 55.0%; Pred. No. 1.2e+02;
Matches 11; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQK 20
|:|:| | | | | | | | |
Db 84 PIIDLFGLNQLSEYTIK 103

RESULT 13
Q3K8F1_PSEPF PRELIMINARY; PRT; 280 AA.
ID Q3K8F1_PSEPF
AC Q3K8F1;
DT 08-NOV-2005, integrated into UniProtKB/TrEMBL.
DT 08-NOV-2005, sequence version 1.
DT 30-MAY-2006, entry version 8.
DE MazG.
GN OrderedLocNames=Pfl_4216;
OS Pseudomonas fluorescens (strain PFO-1).
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=205922;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RG US DOE Joint Genome Institute;
RA Copeland A., Lucas S., Lapidus A., Barry K., Detter J.C., Glavina T.,
RA Hammon N., Irani S., Pittluck S., Saunders E.H., Schmutz J.,
RA Larimer F., Land M., Kyrpides N., Anderson I., Richardson P.;
RT "Complete sequence of Pseudomonas fluorescens pFO-1.";
RL Submitted (AUG-2005) to the EMBL/GenBank/DBJ databases.
CC
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
```

```
CC EMBL; CP000094; ABA75953.1; -; Genomic_DNA.
DR GenomeReviews; CP000094 GR; Pfl_4216.
DR InterPro; IPR011029; DEATH_like.
DR InterPro; IPR012199; MazG.
DR InterPro; IPR011551; MazG_bac.
DR InterPro; IPR004518; MazG_cat.
DR Pfam; PF03819; MazG; 2.
DR PIRSF; PIRSF002844; NTP_pyrophdr_MazG; 1.
DR TIGRFAMs; TIGR00444; mazG; 1.
KW Complete proteome.
SQ SEQUENCE 280 AA; 32085 MW; 0AA804512A53414D CRC64;
Query Match 50.5%; Score 53; DB 2; Length 280;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQ 19
| | | | | | | | | | | | | |
Db 179 PVLDKVRBELDEVLEAMSE 197

RESULT 14
Q2BAJ7_9BACI PRELIMINARY; PRT; 605 AA.
ID Q2BAJ7_9BACI
AC Q2BAJ7;
DT 04-APR-2006, integrated into UniProtKB/TrEMBL.
DT 04-APR-2006, sequence version 1.
DT 13-JUN-2006, entry version 3.
DE Oligoendopeptidase F.
GN ORFNames=B14911_28130;
OS Bacillus sp. NRRL B-14911.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX NCBI_TaxID=313627;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=NRRL B-14911.
RA Siefert J., Ferreira S., Johnson J., Kravitz S., Halpern A.,
RA Remington K., Beeson K., Tran B., Rogers Y.-H., Friedman R.,
RA Venter J.C.;
RL Submitted (FEB-2006) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
CC
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC
CC EMBL; AAOX01000006; EAR66951.1; -; Genomic_DNA.
DR GO; GO:0004222; F:metalloendopeptidase activity; IEA.
DR GO; GO:0006508; P:proteolysis; IEA.
DR InterPro; IPR001567; Pept_M3A_M3B.
DR InterPro; IPR006025; Pept_M_Zn_BS.
DR InterPro; IPR013647; Peptidase_M3_N.
DR InterPro; IPR004438; Peptidase_M3B.
DR Pfam; PF01432; Peptidase_M3; 1.
DR Pfam; PF08439; Peptidase_M3_N; 1.
DR TIGRFAMs; TIGR00181; pepF; 1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN 1.
SQ SEQUENCE 605 AA; 68388 MW; 36DEAY0199190077 CRC64;
Query Match 50.5%; Score 53; DB 2; Length 605;
Best Local Similarity 57.1%; Pred. No. 2.5e+02;
Matches 12; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 1 PVLDLFRELLNELLEALKQKL 21
| | | | | | | | | | | | | |
Db 136 PELEAFRNKLBELLETKKKHL 156

RESULT 15
Q9FZ15_ARATH PRELIMINARY; PRT; 727 AA.
ID Q9FZ15_ARATH
```

```

AC Q9FZ15;
DT 01-MAR-2001, integrated into UniProtKB/TrEMBL.
DT 01-MAR-2001, sequence version 1.
DT 18-APR-2006, entry version 22.
DE Hypothetical protein F1019.1 (Fragment).
GN Name=F1019.1;
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Federspiel N.A., Palm C.J., Conway A.B., Conn L., Hansen N.F.,
RA Altafi H., Nguyen M., Lam B., Southwick A., Miranda M., Brooks S.,
RA Buehler B., Chao Q., Chin C., Choi J., Choi B., Gonzalez A.,
RA Howng B., Johnson-Hopson C., Khan S., Kim C., Koo T., Lee J.M.,
RA Lenz C., Liu A., Liu S., Mukharsky N., Pham P., Sakano H., Shinn P.,
RA Toriumi M., Vaysberg M., Yu G., Ecker J., Theologis A., Davis R.W.;
RA Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
RL -!- SIMILARITY: Belongs to the Ser/Thr protein kinase family.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; AC007152; AAF98207.1; -; Genomic_DNA.
CC -----
DR HSPP; P06239; 3LCK.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0000166; F:nucleotide binding; IEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR011009; Kinase like.
DR InterPro; IPR000719; Prot_kinase.
DR InterPro; IPR008271; Ser_Thr_kin_AS.
DR Pfam; PF00069; Pkinase; 1.
DR ProDom; PD000001; Prot_kinase; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR ATP-binding; Hypothetical protein; Kinase; Nucleotide-binding;
KW Serine/threonine-protein kinase; Transferase.
FT NON TER 1
SQ SEQUENCE 727 AA; 81129 MW; BEF55B9646E0459E CRC64;

Query Match 50.5%; Score 53; DB 2; Length 727;
Best Local Similarity 52.4%; Pred.No. 3e+02;
Matches 11; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKL 21
Db 239 PLLDRFRGVNLNLEMCRRKV 259

Search completed: August 16, 2007, 22:48:32
Job time : 351 secs

```

GenCore version 6.2.1  
Copyright (c) 1993 - 2007 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: August 16, 2007, 22:38:56 ; Search time 213 Seconds  
(without alignments)  
50.541 Million cell updates/sec

Title: US-10-715-895A-4  
Perfect score: 105  
Sequence: 1 PVLDFRELLNELLEALKOKLK 22

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2782304 seqs, 489333398 residues

Total number of hits satisfying chosen parameters: 2782304

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A Geneseq\_200701.\*  
1: Geneseqp1980s.\*  
2: Geneseqp1990s.\*  
3: Geneseqp2000s.\*  
4: Geneseqp2001s.\*  
5: Geneseqp2002s.\*  
6: Geneseqp2003as.\*  
7: Geneseqp2003bs.\*  
8: Geneseqp2004s.\*  
9: Geneseqp2005s.\*  
10: Geneseqp2006s.\*  
11: Geneseqp2007s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	105	100.0	22	2 AAY01708	Peptide f
2	105	100.0	22	2 AAY18683	Lecithin:
3	105	100.0	22	2 AAY18709	Lecithin:
4	105	100.0	22	2 AAY18779	Lecithin:
5	105	100.0	22	2 AAY18963	Lecithin:
6	105	100.0	22	2 AAY18937	Lecithin:
7	105	100.0	22	2 AAY19033	Lecithin:
8	105	100.0	22	2 AAY19191	Lecithin:
9	105	100.0	22	2 AAY19217	Lecithin:
10	105	100.0	22	2 AAY19287	Lecithin:
11	105	100.0	22	2 AAY18446	Lecithin:
12	105	100.0	22	2 AAY18516	Lecithin:
13	105	100.0	22	2 AAY18420	Lecithin:
14	105	100.0	22	8 ADG20900	Apolipop
15	105	100.0	22	8 ADG20926	Apolipop
16	105	100.0	22	8 ADG20996	Apolipop
17	105	100.0	22	8 ADJ32938	Apo lipop
18	105	100.0	22	8 ADJ32886	Apo lipop
19	105	100.0	22	8 ADJ32868	Apo lipop
20	105	100.0	22	8 ADJ32859	Apo lipop
21	105	100.0	22	8 ADJ32842	Apo lipop
22	105	100.0	23	8 ADJ32843	Apo lipop

23	102	97.1	22	2 AAY18686	Lecithin:
24	102	97.1	22	2 AAY18940	Lecithin:
25	102	97.1	22	2 AAY19194	Lecithin:
26	102	97.1	22	2 AAY18423	Lecithin:
27	102	97.1	22	8 ADG20903	Apolipop
28	102	97.1	22	8 ADJ32845	Apo lipop
29	101	96.2	22	2 AAY18701	Lecithin:
30	101	96.2	22	2 AAY18680	Lecithin:
31	101	96.2	22	2 AAY18934	Lecithin:
32	101	96.2	22	2 AAY18955	Lecithin:
33	101	96.2	22	2 AAY19209	Lecithin:
34	101	96.2	22	2 AAY19188	Lecithin:
35	101	96.2	22	2 AAY18438	Lecithin:
36	101	96.2	22	2 AAY18417	Lecithin:
37	101	96.2	22	8 ADG20918	Apolipop
38	101	96.2	22	8 ADJ32839	Apo lipop
39	101	96.2	22	8 ADJ32839	Apo lipop
40	101	96.2	22	8 ADJ32860	Apo lipop
41	100	95.2	22	2 AAY18685	Lecithin:
42	100	95.2	22	2 AAY18775	Lecithin:
43	100	95.2	22	2 AAY18806	Lecithin:
44	100	95.2	22	2 AAY18705	Lecithin:
45	100	95.2	22	2 AAY18706	Lecithin:

ALIGNMENTS

RESULT 1  
AAY01708  
ID AAY01708 standard; peptide; 22 AA.  
XX  
XX AAY01708;  
AC  
DT 24-JUN-1999 (first entry)  
XX  
DE Peptide for making peptide-lipid complex by co-lyophilization approach.  
XX  
KW Peptide-lipid complex; co-lyophilization approach; liposome;  
KW compound storage; vaccine; dyslipoproteinemia; hypercholesterolemia;  
KW hypertriglyceridemia; low HDL; apolipoprotein A-1 deficiency;  
KW cardiovascular disease; atherosclerosis; septic shock;  
KW infectious disease.  
XX  
OS Synthetic.  
XX  
EN WO9917740-A1.  
XX  
PD 15-APR-1999.  
XX  
PF 28-SEP-1998; 98WO-US020330.  
XX  
PR 02-OCT-1997; 97US-00942597.  
XX  
PA (DASS/) DASSEUX J.  
XX  
PI Dasseux J;  
XX  
XX WPI; 1999-277181/23.  
XX  
PT Preparation of a lyophilized peptide/lipid product - by co-lyophilization  
of peptides and solubilizing in lipid.  
XX  
PS Example 1; Page 18; 42pp; English.  
XX  
CC The present sequence represents a peptide used to make peptide-lipid  
complexes by the co-lyophilization approach of the invention. Preparation  
of a lyophilized peptide/lipid product comprises co-lyophilization of one  
or more peptides which are able to adopt an amphipathic conformation or  
their analogues, and one or more lipids in a solvent system to form a  
peptide/lipid product which can be rehydrated to form peptide/lipid  
complexes, solubilizing at least one amphipathic peptide or its analog in  
a first solution, solubilizing at least one lipid in a second solution

CC which is miscible with the first solution, combining the solutions and  
 CC lyophilizing to form a product which can be rehydrated to form  
 CC peptide/lipid complexes. The method is used for generating stable  
 CC peptide/lipid vesicles and complexes such as micellar, spherical and  
 CC discoidal complexes in bulk preparations and in smaller units e.g.  
 CC dosages. Liposomes are known to be used for delivery vehicles for drugs,  
 CC cosmetics and bioactive compounds. The method may also be used for  
 CC storage of compounds which may otherwise be unstable or insoluble in the  
 CC absence of lipids or for formulation of products for treatment or  
 CC prevention of human diseases such as co-presentation of antigens in  
 CC vaccines, treatment or prevention of dyslipoproteinaemias, e.g.  
 CC hypercholesterolemia, hypertriglyceridemia, low HDL and apolipoprotein A-  
 CC 1 deficiency, cardiovascular disease such as atherosclerosis, septic  
 CC shock or infectious diseases. The method can also be used in the  
 CC preparation of complexes which can be used as carriers for drugs, as  
 CC vectors (to deliver drugs, DNA and genes) e.g. to the liver or to extra  
 CC hepatic cells or as scavengers to trap toxins such as pesticides and LPS  
 XX  
 XX Sequence 22 AA;

Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDLFRELLNELLEALKQK 22  
 DB 1 PVLDLFRELLNELLEALKQK 22

RESULT 2  
 AAY18683  
 ID AAY18683 standard; peptide; 22 AA.  
 XX  
 AC AAY18683;  
 XX  
 DT 09-JUL-1999 (first entry)  
 XX

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.

XX Synthetic.  
 OS Homo sapiens.  
 OS  
 FN WO9916408-A2.  
 XX  
 XX 08-APR-1999.  
 PD  
 PF 28-SEP-1998; 98WO-US020328.  
 XX  
 PR 29-SEP-1997; 97US-00940093.

XX (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 XX  
 DR WPI; 1999-277031/23.  
 XX  
 PT Peptide agonists of apolipoprotein A-I.  
 XX  
 PS Example; Page 104; 152pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18880 to  
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 XX exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDLFRELLNELLEALKQK 22  
 DB 1 PVLDLFRELLNELLEALKQK 22

RESULT 3  
 AAY18709  
 ID AAY18709 standard; peptide; 22 AA.  
 XX  
 AC AAY18709;

XX  
 DT 09-JUL-1999 (first entry)  
 XX

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.

XX Synthetic.  
 OS Homo sapiens.  
 OS  
 FN WO9916408-A2.  
 XX  
 XX 08-APR-1999.  
 PD  
 PF 28-SEP-1998; 98WO-US020328.  
 XX  
 PR 29-SEP-1997; 97US-00940093.

XX (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 XX  
 DR WPI; 1999-277031/23.  
 XX

PT Peptide agonists of apolipoprotein A-I.

PS Example; Page 105; 152pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at

CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to  
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQKLIK 22  
 DB 1 PVLDLFRELLNELLEALKQKLIK 22  
 RESULT 4  
 AAY18779  
 ID AAY18779 standard; peptide; 22 AA.  
 AC AAY18779;  
 XX  
 XX 09-JUL-1999 (first entry)  
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #100.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN W09916408-A2.  
 PD 08-APR-1999.  
 XX  
 XX 28-SEP-1998; 98WO-US020328.  
 XX 29-SEP-1997; 97US-00940093.  
 XX (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 WPI; 1999-277031/23.  
 XX  
 XX Peptide agonists of apolipoprotein A-I.  
 PT  
 PS Example; Page 109; 152pp; English.  
 XX  
 CC The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to  
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQKLIK 22  
 DB 1 PVLDLFRELLNELLEALKQKLIK 22

Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQKLIK 22  
 DB 1 PVLDLFRELLNELLEALKQKLIK 22  
 RESULT 5  
 AAY18963  
 ID AAY18963 standard; peptide; 22 AA.  
 XX  
 AC AAY18963;  
 XX  
 XX 09-JUL-1999 (first entry)  
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN W09916458-A1.  
 PD 08-APR-1999.  
 XX  
 XX 28-SEP-1998; 98WO-US020326.  
 XX 29-SEP-1997; 97US-00940096.  
 XX (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 WPI; 1999-277034/23.  
 XX  
 XX Peptide agonists of apolipoprotein A-I.  
 PT  
 PS Example; Page 108; 254pp; English.  
 XX  
 CC The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to  
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQKLIK 22  
 DB 1 PVLDLFRELLNELLEALKQKLIK 22

RESULT 6  
 AAY18937  
 ID AAY18937 standard; peptide; 22 AA.  
 AC AAY18937;  
 XX  
 XX  
 DT 09-JUL-1999 (first entry)  
 XX  
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9916458-A1.  
 XX  
 PD 08-APR-1999.  
 XX  
 PF 28-SEP-1998; 98WO-US020326.  
 XX  
 PR 29-SEP-1997; 97US-00940096.  
 XX  
 PA (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 XX  
 DR WPI; 1999-277034/23.  
 XX  
 PT Peptide agonists of apolipoprotein A-I.  
 XX  
 PS Example; Page 107; 254pp; English.  
 XX  
 CC The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to  
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQK 22  
 |||||  
 DB 1 PVLDLFRELLNELLEALKQK 22  
 |||||  
 RESULT 7  
 AAY19033  
 ID AAY19033 standard; peptide; 22 AA.  
 XX  
 AC AAY19033;  
 XX  
 XX  
 DT 14-JUL-1999 (first entry)  
 XX  
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9916458-A1.  
 XX  
 PD 08-APR-1999.  
 XX  
 PF 28-SEP-1998; 98WO-US020326.  
 XX  
 PR 29-SEP-1997; 97US-00940096.  
 XX  
 PA (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 XX  
 DR WPI; 1999-277034/23.  
 XX  
 PT Peptide agonists of apolipoprotein A-I.  
 XX  
 PS Example; Page 107; 254pp; English.  
 XX  
 CC The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to  
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQK 22  
 |||||  
 DB 1 PVLDLFRELLNELLEALKQK 22  
 |||||

DT 09-JUL-1999 (first entry)  
 XX  
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #100.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9916458-A1.  
 XX  
 PD 08-APR-1999.  
 XX  
 PF 28-SEP-1998; 98WO-US020326.  
 XX  
 PR 29-SEP-1997; 97US-00940096.  
 XX  
 PA (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 XX  
 DR WPI; 1999-277034/23.  
 XX  
 PT Peptide agonists of apolipoprotein A-I.  
 XX  
 PS Example; Page 112; 254pp; English.  
 XX  
 CC The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to  
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQK 22  
 |||||  
 DB 1 PVLDLFRELLNELLEALKQK 22  
 |||||  
 RESULT 8  
 AAY19191  
 ID AAY19191 standard; peptide; 22 AA.  
 XX  
 AC AAY19191;  
 XX  
 DT 14-JUL-1999 (first entry)  
 XX  
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.  
 XX  
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;  
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;  
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;  
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9916458-A1.  
 XX  
 PD 08-APR-1999.  
 XX  
 PF 28-SEP-1998; 98WO-US020326.  
 XX  
 PR 29-SEP-1997; 97US-00940096.  
 XX  
 PA (DASS/) DASSEUX J.  
 PA (SEKU/) SEKUL R.  
 PA (BUTT/) BUTTNER K.  
 PA (CORN/) CORNUT I.  
 PA (METZ/) METZ G.  
 XX  
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;  
 XX  
 DR WPI; 1999-277034/23.  
 XX  
 PT Peptide agonists of apolipoprotein A-I.  
 XX  
 PS Example; Page 112; 254pp; English.  
 XX  
 CC The present invention describes an agonist (A) of apolipoprotein A-I  
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an  
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid  
 CC complexes, are used to treat or prevent diseases associated with  
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,  
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I  
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for  
 CC treating septic shock. When labeled, (A) can also be used diagnostically  
 CC to measure serum levels of HDL, in particular the HDL subpopulation that  
 CC is involved in retrograde cholesterol transport, also to image HDL at  
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to  
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity  
 CC exhibiting core peptides, which are apoA-I agonists  
 XX  
 SQ Sequence 22 AA;  
 Query Match 100.0%; Score 105; DB 2; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 9.2e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 PVLDLFRELLNELLEALKQK 22  
 |||||  
 DB 1 PVLDLFRELLNELLEALKQK 22  
 |||||



KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;  
 KW septic shock.

XX Synthetic.

OS Homo sapiens.

XX WO9916459-A1.

PN 08-APR-1999.

XX 28-SEP-1998; 98WO-US020327.

XX 29-SEP-1997; 97US-00940095.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

PA (DUFO/) DUFOURCQ J.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX WPI; 1999-277035/23.

XX Peptide agonists of apolipoprotein A-I.

XX Claim 19; Page 155; 280pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I

CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

CC complexes, are used to treat or prevent diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

CC treating septic shock. When labeled, (A) can also be used diagnostically

CC to measure serum levels of HDL, in particular the HDL subpopulation that

CC is involved in retrograde cholesterol transport, also to image HDL at

CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

Query Match 100.0%; Score 105; DB 2; Length 22;

Best Local Similarity 100.0%; Pred. No. 9.2e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDFRELLNELLEALKQKLIK 22

DB 1 PVLDFRELLNELLEALKQKLIK 22

RESULT 9

AAV19217

ID AAY19217 standard; peptide; 22 AA.

AC AAY19217;

XX 14-JUL-1999 (first entry)

XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

KW septic shock.

XX Synthetic.

OS Homo sapiens.

XX

PN WO9916459-A1.

XX 08-APR-1999.

XX 28-SEP-1998; 98WO-US020327.

XX 29-SEP-1997; 97US-00940095.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

PA (DUFO/) DUFOURCQ J.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX WPI; 1999-277035/23.

XX Peptide agonists of apolipoprotein A-I.

XX Example; Page 117; 280pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I

CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

CC complexes, are used to treat or prevent diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

CC treating septic shock. When labeled, (A) can also be used diagnostically

CC to measure serum levels of HDL, in particular the HDL subpopulation that

CC is involved in retrograde cholesterol transport, also to image HDL at

CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

Query Match 100.0%; Score 105; DB 2; Length 22;

Best Local Similarity 100.0%; Pred. No. 9.2e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PVLDFRELLNELLEALKQKLIK 22

DB 1 PVLDFRELLNELLEALKQKLIK 22

RESULT 10

AAV19287

ID AAY19287 standard; peptide; 22 AA.

XX AAY19287;

XX 14-JUL-1999 (first entry)

XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #100.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

KW septic shock.

XX Synthetic.

OS Homo sapiens.

XX WO9916459-A1.

XX 08-APR-1999.

XX 28-SEP-1998; 98WO-US020327.

XX

XX	Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J; WPI; 1999-254921/21.
XX	Nucleic acid encoding apoproteinA-I agonist peptides. Example; Page 135; 232pp; English.
XX	The present invention describes a nucleic acid (A) encoding an apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog, which forms an amphipathic alpha-helix in presence of lipids. (A), optionally as a complex with lipids, and host cells that contain (A), are useful for gene therapy, or prevention, of diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I deficiency, hypertriglyceridemia and metabolic syndrome, also to treat endotoxemia (septic shock). Host cells containing (A) can also be used to study the role of apoA-I in lipid metabolism. (B) can be used diagnostically, e.g. to measure serum HDL (particularly its subpopulation involved in retrograde cholesterol transport) and for imaging the circulatory system or HDL accumulations at fatty streaks. The present sequence represents a peptide from the present invention
XX	Sequence 22 AA;
SQ	Query Match            100.0%; Score 105; DB 2; Length 22; Best Local Similarity 100.0%; Pred. No. 9.2e-07; Matches    22; Conservative    0; Mismatches    0; Indels    0; Gaps    0;
QY	1 PVLDFRELLNELLEALKKQLK 22 
DB	1 PVLDFRELLNELLEALKKQLK 22 
RESULT 12	AAV18516
ID	AAV18516 standard; peptide; 22 AA.
AC	AAV18516;
XX	09-JUL-1999 (first entry)
DE	Lecithin:cholesterol acyltransferase activation exhibiting peptide #100.
KW	Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I; cardiovascular disease; atherosclerosis; restenosis; LCAT; hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
OS	Synthetic.
OS	Homo sapiens.
PN	WO9916409-A2.
PD	08-APR-1999.
PF	28-SEP-1998; 98WO-US020329.
PR	29-SEP-1997; 97US-00940136.
PA	(DASS/) DASSEUX J. (SEKU/) SEKUL R. (BUTT/) BUTTNER K. (CORN/) CORNUT I. (METZ/) METZ G. (DUFO/) DUFOURCO J.
PI	Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J; WPI; 1999-277035/23.
PT	Peptide agonists of apolipoprotein A-I. Example; Page 121; 280pp; English.
PS	The present invention describes an agonist (A) of apolipoprotein A-I (apoa-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency, hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAV19188 to AAV19441 represent lecithin:cholesterol acyltransferase (LCAT) activity exhibiting core peptides, which are apoA-I agonists
XX	Sequence 22 AA;
SQ	Query Match            100.0%; Score 105; DB 2; Length 22; Best Local Similarity 100.0%; Pred. No. 9.2e-07; Matches    22; Conservative    0; Mismatches    0; Indels    0; Gaps    0;
QY	1 PVLDFRELLNELLEALKKQLK 22 
DB	1 PVLDFRELLNELLEALKKQLK 22 
RESULT 11	AAV18446
ID	AAV18446 standard; peptide; 22 AA.
AC	AAV18446;
XX	09-JUL-1999 (first entry)
DE	Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.
KW	Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I; cardiovascular disease; atherosclerosis; restenosis; LCAT; hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
OS	Synthetic.
OS	Homo sapiens.
PN	WO9916409-A2.
PD	08-APR-1999.
PF	28-SEP-1998; 98WO-US020329.
PR	29-SEP-1997; 97US-00940136.
PA	(DASS/) DASSEUX J. (SEKU/) SEKUL R. (BUTT/) BUTTNER K. (CORN/) CORNUT I. (METZ/) METZ G. (DUFO/) DUFOURCO J.

PS Example; Page 157; 232pp; English.

XX The present invention describes a nucleic acid (A) encoding an

CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,

CC which forms an amphipathic alpha-helix in presence of lipids. (A),

CC optionally as a complex with lipids, and host cells that contain (A), are

CC useful for gene therapy, or prevention, of diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I

CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat

CC endotoxemia (septic shock). Host cells containing (A) can also be used

CC to study the role of apoA-I in lipid metabolism. (B) can be used

CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation

CC involved in retrograde cholesterol transport) and for imaging the

CC circulatory system or HDL accumulations at fatty streaks. The present

CC sequence represents a peptide from the present invention

XX

SQ Sequence 22 AA;

Query Match 100.0%; Score 105; DB 2; Length 22;

Best Local Similarity 100.0%; Pred. No. 9.2e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22

Db 1 PVLDFRELLNELLEALKQKLIK 22

RESULT 13

AA18420

ID AAY18420 standard; peptide; 22 AA.

XX

AC AAY18420;

XX

DT 09-JUL-1999 (first entry)

XX

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.

XX

KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;

KW cardiovascular disease; atherosclerosis; restenosis; LCAT;

KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9916409-A2.

XX

PD 08-APR-1999.

XX

XX

PF 28-SEP-1998; 98WO-US020329.

XX

XX

PR 29-SEP-1997; 97US-00940136.

XX

XX

PA (DASS//) DASSEUX J.

PA (SEKU//) SEKUL R.

PA (BUTT//) BUTTNER K.

PA (CORN//) CORNUT I.

PA (METZ//) METZ G.

PA (DUFO//) DUFOURCQ J.

XX

XX

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX

DR WPI; 1999-254921/21.

XX

XX

PT Nucleic acid encoding apolipoproteinA-I agonist peptides.

XX

PS Claim 18; Page 127; 232pp; English.

XX

XX

CC The present invention describes a nucleic acid (A) encoding an

CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,

CC which forms an amphipathic alpha-helix in presence of lipids. (A),

CC optionally as a complex with lipids, and host cells that contain (A), are

CC useful for gene therapy, or prevention, of diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I

CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat

CC endotoxemia (septic shock). Host cells containing (A) can also be used

CC to study the role of apoA-I in lipid metabolism. (B) can be used

CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation

CC involved in retrograde cholesterol transport) and for imaging the

CC circulatory system or HDL accumulations at fatty streaks. The present

CC sequence represents a peptide from the present invention

XX

SQ Sequence 22 AA;

Query Match 100.0%; Score 105; DB 2; Length 22;

Best Local Similarity 100.0%; Pred. No. 9.2e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PVLDFRELLNELLEALKQKLIK 22

Db 1 PVLDFRELLNELLEALKQKLIK 22

RESULT 14

ADG20900

ID ADG20900 standard; peptide; 22 AA.

XX

AC ADG20900;

XX

DT 26-FEB-2004 (first entry)

XX

DE Apolipoprotein A-I agonist peptide seq id 4.

XX

KW apolipoprotein A-I; ApoA-I; agonist; peptide analogue;

KW amphipathic alpha-helix; dyslipidaemia; hypercholesterolaemia;

KW cardiovascular disease; atherosclerosis; restenosis;

KW high density lipoprotein; HDL; ApoA-I deficiency; hypertriglyceridaemia;

KW metabolic syndrome; septic shock.

XX

OS Synthetic.

XX

PN US2003203842-A1.

XX

PD 30-OCT-2003.

XX

XX

PF 15-MAR-2002; 2002US-00099836.

XX

XX

PR 01-DEC-1999; 99US-00453834.

XX

XX

PA (DASS//) DASSEUX J.

PA (SEKU//) SEKUL R.

PA (BUTT//) BUTTNER K.

PA (CORN//) CORNUT I.

PA (METZ//) METZ G.

PA (DUFO//) DUFOURCQ J.

XX

XX

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX

DR WPI; 2004-010524/01.

XX

XX

PT Novel apolipoprotein agonist treating subject suffering from disorder

PT associated with dyslipidaemia such as hypercholesterolemia, cardiovascular

PT disease, atherosclerosis, restenosis, hypertriglyceridemia or metabolic

PT syndrome.

XX

XX

PS Claim 19; SEQ ID NO 4; 146pp; English.

XX

XX

CC The invention describes an apolipoprotein A-I (ApoA-I) agonist (A)

CC comprising a 15-29 residue peptide or peptide analogue which forms an

CC amphipathic alpha-helix in the presence of lipids or its salt. (A) is

CC useful for treating a subject suffering from a disorder associated with

CC dyslipidaemia (hypercholesterolaemia, cardiovascular disease,

CC atherosclerosis, restenosis, high density lipoprotein (HDL) or ApoA-I

CC deficiency, hypertriglyceridaemia or metabolic syndrome) or septic shock.

CC This is the amino acid sequence of a ApoA-I agonist peptide.

QY 1 PVLDLFRELLNELLEALKQKLK 22

AI1256 - Listeria monocytogenes (strain EGD-e)  
hypothetical protein lmo1457 [imported]





<p>A:Molecule type: DNA  A:Residues: 1-303 &lt;PAR&gt;  A:Cross-references: UNIPROT:Q9PI08; UNIPARC:UPI000012C5CC; GB:ALL139075; GB:ALL111168; NID:  A:Experimental source: serotype O2, strain NCTC 11168  C:Genetics:  A:Gene: Cj0501; Cj0503c  C:Keywords: lyase</p>									
<p>Query Match 44.8%; Score 47; DB 2; Length 303;  Best Local Similarity 47.4%; Pred. No. 62;  Matches 9; Conservative 6; Mismatches 4; Indels 0; Gaps 0;</p>									
Qy	4	DLFRELNLLEALKOKLK	22						
Db	196	DLYKEHVNDHVEILKEKLK	214						
<p>RESULT 12</p>									
<p>C69453  transposase homolog - Archaeoglobus fulgidus  C:Species: Archaeoglobus fulgidus  C:Date: 05-Dec-1997 #sequence_revision 05-Dec-1997 #text_change 09-Jul-2004  C:Accession: C69453  R:Klenk, H.P.; Clayton, R.A.; Tomb, J.F.; White, O.; Nelson, K.E.; Ketchum, K.A.; Dodson  ; Fleischmann, R.D.; Quackenbush, J.; Lee, N.H.; Sutton, G.G.; Gill, S.; Kirkness, E.F.  Glodek, A.; Zhou, L.; Overbeek, R.; Gocayne, J.D.; Weidman, J.F.; McDonald, L.  Nature 390, 364-370, 1997  A:Authors: Uterback, T.; Cotton, M.D.; Spriggs, T.; Artiach, P.; Kaine, B.P.; Sykes, S.  Smith, H.O.; Woese, C.R.; Venter, J.C.  A:Title: The complete genome sequence of the hyperthermophilic, sulfate-reducing archaea  A:Reference number: A69250; MUID:98049343; PMID:9389475  A:Accession: C69453  A:Status: preliminary; nucleic acid sequence not shown; translation not shown  A:Molecule type: DNA  A:Residues: 1-344 &lt;KLE&gt;  A:Cross-references: UNIPROT:O28645; UNIPARC:UPI0000056C62; GB:AE000990; GB:AE000782; NID:</p>									
<p>Query Match 44.8%; Score 47; DB 2; Length 344;  Best Local Similarity 52.9%; Pred. No. 71;  Matches 9; Conservative 4; Mismatches 4; Indels 0; Gaps 0;</p>									
Qy	6	FRELNLLEALKOKLK	22						
Db	267	YRKLVKRLFEGLKQNLK	283						
<p>RESULT 13</p>									
<p>JC5670  lysosomal membrane 85K glycoprotein precursor - mouse  C:Species: Mus musculus (house mouse)  C:Date: 20-Nov-1997 #sequence_revision 20-Nov-1997 #text_change 09-Jul-2004  C:Accession: JC5670  R:Tabuchi, N.; Akasaki, K.; Sasaki, T.; Kanda, N.; Tsuji, H.  J. Biochem. 122, 756-763, 1997  A:Title: Identification and characterization of a major lysosomal membrane glycoprotein,  A:Reference number: JC5670; MUID:98060500; PMID:9399579  A:Accession: JC5670  A:Molecule type: mRNA  A:Residues: 1-478 &lt;TAB&gt;  A:Cross-references: UNIPROT:O35114; UNIPARC:UPI00000231D6; GB:AB008553; NID:g2618485; PFT  C:Comment: This protein is involved in sequestration of particulate cytoplasmic proteins  C:Superfamily: lysosomal integral membrane protein II  F:1-26/Domain: signal sequence #status predicted &lt;SIG&gt;  F:433-458/Domain: transmembrane #status predicted &lt;TM&gt;  F:474-475/Region: endosomal/lysosomal sorting signal</p>									
<p>Query Match 44.8%; Score 47; DB 2; Length 478;  Best Local Similarity 52.6%; Pred. No. 1e+02;  Matches 10; Conservative 4; Mismatches 5; Indels 0; Gaps 0;</p>									
Qy	3	LDLRELNLLEALKOKLK	21						
Db	149	LTLLRELIEAMLKAYOOKL	167						



**STIC Database Tracking Number: 234005**

**To: MARK SHIBUYA**  
**Location: REM-2A29 / Mailbox 2C18**  
**Art Unit: 1639**  
**Thursday, August 16, 2007**

**Case Serial Number: 10/715895**

**From: HUYEN-TRAN TON-NU**  
**Location: EIC 1600**  
**REM-1D58 / REM-1B61**  
**Phone: (571)272-9218**

**[huyen-tran.ton-nu@uspto.gov](mailto:huyen-tran.ton-nu@uspto.gov)**

## Search Notes

Dear Examiner SHIBUYA:

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services.

Huyen-Tran Ton-nu  
Technical Information Specialist  
STIC Biotech/Chem Library  
(571) 272-9218